Stock Code：4188

安克生醫股份有限公司
AmCad BioMed Corporation

Handbook for the 2026 Annual Meeting of Shareholders

Form of meeting：Physical Meeting

Meeting Time：June 12, 2026

Meeting Place：3rd Fl., No.10 Shih-er Rd.,Yangmei District, Taoyuan City

Table of Contents

I. Meeting Procedures

AmCad BioMed Corporation
Procedure for the 2026 Annual Meeting of Shareholders

1.Calling the Meeting to Order (Report the total number of shares present)

2.Chairperson Remarks

3.Report Items

4.Acknowledged Items

5.Discussion Item

6.Election Item

7.Other Item

8.Extemporary Motion

9.Adjournment

II. Meeting Agenda

AmCad BioMed Corporation
Procedure for the 2026 Annual Meeting Agendas

Form of meeting：Physical Meeting

Meeting Time：9:00a.m., Friday , June 12, 2026

Meeting Place：3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

1. Call the Meeting to Order (Report the total number of shares present)
2. Chairperson Remarks
3. Report Items
   (1) The 2025 Business Report.
   (2) The 2025 Audit Committee's Review Report.
   (3) Report on the Execution Status of the Private Placement of Common Shares Approved at the 2025 Annual General Shareholders' Meeting.
   (4) Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and Evaluation Results on the Reasonableness of Each Expenditure Item as Assessed by the Underwriter.
   (5) Report on the Revision to the Sustainable Development Best Practice Principles.
4. Acknowledged Items
   (1) Adoption of 2025 the Financial Statements and Business Report.
   (2) Adoption of the Proposal for 2025 Deficit Compensation.
5. Discussion Item
   Discussion on the Proposal for Private Placement of Common Shares through Cash Capital Increase.
6. Election Item
   Elections of board directors.
7. Other Item
   Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business.
8. Extemporary Motions
9. Adjournment

1. Report Items

(1) The 2025 Business Report.

Explanation：Please refer to Attachment 1 (pages 13~15) for detailed Business Reports.

(2) The 2025 Audit Committee's Review Report.

Explanation：Please refer to Attachment 2 (page 16) for 2025 Audit Committee's ReviewReport.

(3) Report on the Implementation Status of the Private Placement of Common Shares Approved at the 2025 Annual General Shareholders' Meeting.

Explanation：a. On June 3, 2025, the Company's shareholders approved a resolution at the Annual General Shareholders' Meeting to conduct a private placement of common shares through cash capital increase. Pursuant to Article 43-6 of the Securities and Exchange Act, privately placed securities must be executed within one year from the date of the shareholders' resolution.

b. As the one-year term had expired, no further action was taken.

c. Report.

(4) Report on the Implementation Status of the Sound Business Operation Plan, the Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases, Actual Use of Funds, and the Underwriter's Evaluation Results on the Reasonableness of Each Expenditure Item.

Explanation：For details on the Company's implementation status of the sound business operation plan, the progress of fund utilization from the 2015 and 2024 cash capital increases, actual use of funds, and the underwriter's evaluation results on the reasonableness of each expenditure item, please refer to Attachment 3 (pages 17～37) of this handbook for your review.

(5) Report on the Revision of the"Sustainable Development Best Practice Principles".

Explanation：a. In response to regulatory amendments and practical needs, relevant provisions have been added and revised concerning the new Corporate Governance Blueprint, as well as the enhancement of biodiversity and ecosystem conservation, sustainable use of resources, and fair and equitable benefit sharing. This case has been passed by the resolution of the the Board of Directors on February 24, 2026,revising certain provisions of the Company's "Sustainable Development Best Practice Principles ".

b. Please refer to Attachment 4 (page 38～40) for The Comparison Table of "Sustainable Development Best Practice Principles".

c. Report.

2. Acknowledged Items

Proposal 1

Subject：Adoption of 2025 the Financial Statements and Business Report.

(Proposed by the Board of Directors)

Explanation：(1) The Company’s 2025 Financial Statements and Business Report have been approved by the Audit Committee and resolved by the Board of Directors on February 24, 2026. The Financial Statements have been audited and certified by Ernst & Young Accountants Wang, Yahn-Jyun and Yu, Chien-Ju, and issued "Unqualified Opinion".

(2) Please refer to Attachment 1 (page 13~15) for detailed Business Reports and Attachment 5 (page 41~60) for Financial Statements.

(3) Please acknowledge.

Resolution：

Proposal 2

Subject：Adoption of the Proposal for 2025 Deficit Compensation.

(Proposed by the Board of Directors)

Explanation：(1) The Company had an accumulated deficit to be offset at the beginning of the period of NT$199,320,188. After adding NT$1,956,660 from the disposal of financial assets measured at fair value through other comprehensive income and deducting the 2025 net loss after tax of NT$55,718,573, the ending accumulated deficit to be offset amounted to NT$253,082,101.

(2) This case has been approved by the Audit Committee and the Board of Directors on February 24, 2026.

(3) Please refer to 2025 Deficit Compensation as follows：

Unit: NT$

Item	Amount
Losses to be made up at the beginning of the period	(199,320,188)
Plus：Disposal of financial assets measured at fair value through other comprehensive income	1,956,660
Less：Net loss after tax in 2025	(55,718,573)
Losses to be made up at the end of the period	(253,082,101)

Chairman：Lee Yi-Li　General Manager：Lee Yi-Li　Accounting supervisor：Danica Dai

(4) Please acknowledge.

Resolution：

3. Discussion Item

Subject：Proposal for Private Placement of Common Shares through Cash Capital Increase.

(Proposed by the Board of Directors)

Explanation：(1) To accelerate product promotion and enhance the Company's revenue and profitability, it is proposed to conduct a private placement of common shares within a limit of no more than 15,000,000 shares.

(2) Pursuant to Article 43-6 of the Securities and Exchange Act and the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the following matters regarding the private placement of common shares are hereby explained：

i.Basis and Reasonableness of Pricing：

(i)The price per share for the private placement shall not be lower than 80% of the reference price. The reference price shall be the higher of the following two averages.

1-1The simple arithmetic average of the closing prices of the Company's common shares for either 1, 3, or 5 business days prior to the pricing date, adjusted for any ex-dividend and ex-rights effects, and reinstated for any capital reduction.

1-2The simple arithmetic average of the closing prices of the Company's common shares for the 30 business days prior to the pricing date, also adjusted for any ex-dividend and ex-rights effects, and reinstated for any capital reduction.

The actual pricing date and private placement price will be determined by the Board of Directors, within the authorized range approved by the shareholders' meeting, based on negotiations with specific investors in the future.

(ii)In addition to complying with the relevant provisions of the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the pricing rationale also considers that privately placed securities shall be subject to a three-year transfer restriction starting from the delivery date. Moreover, within this period, the securities may not be registered for public issuance or listed on the stock exchange. Therefore, the pricing is deemed reasonable.

ii.Method of Selecting Specific Investors：

(i) The private placement targets shall be limited to specific investors as defined in Article 43-6 of the Securities and Exchange Act and in accordance with the Financial Supervisory Commission's directive No. 1120383220 dated September 12, 2023.

(ii) The Company has not yet confirmed any subscribers for the private placement. However, if the subscribers are insiders or related parties, their selection method, purpose of participation, and relationship with the Company will be explained as follows：

Subscriber(s)	Selection Method and Purpose	Relationship with the Company
Phytohealth Corp.	To ensure the long-term stability of the Company's operations	Parent Company
Maywufa Company Limited.	To ensure the long-term stability of the Company's operations	Affiliates

Disclosure Requirements if the Subscriber is a Corporate Entity：

Corporate Subscriber	The names and shareholding percentages of its top ten shareholders		Relationship with the Company
	Name	Shareholding Percentage	
Phytohealth Corp. (As recorded in the shareholders' register as of April 11, 2026)	Maywufa Company Ltd. Representative：Lee Chen-Chia	19.00% 0.15%	Corporate Director Director
	Yun Cheng Investment Corporation	0.90%	NA
	Chen Qing-Tang	0.60%	NA
	Zheng An-Hang	0.55%	NA
	Wu Yu-Kun	0.53%	NA
	Chang Te-Rong	0.52%	NA
	Lu Xue-Chang	0.50%	NA
	Wu Zhao-Xiong	0.50%	NA
	National Defense Education Foundation Research Foundation	0.48%	NA
	Wu Li-Hua	0.47%	NA
Maywufa Company Limited. (As recorded in the shareholders' register as of April 12, 2026)	Cheng Yi Investment Company Ltd. Representative：Lee Chen-Chia	17.75% 2.03%	NA Director
	Phytohealth Corp. Representative：Lee Yi-Li	12.59% 1.05%	Corporate Director Chairperson and CEO
	Li Ling Investment Company Ltd. Representative：Lee Chen-Chia	11.25% 2.03%	NA Director
	Chen Wen-Hwa	2.71%	NA
	Cheng Hsin Investment Company Ltd. Representative：Lee Chen-Chia	2.36% 2.03%	NA Director

	Lee Chen-Chia	2.03%	Director
	Lee Yi-Li	1.05%	Chairperson and CEO
	Yi Xin International Company Ltd.	1.04%	NA
	Representative：Lee Yu-Chia	0.08%	NA
	Lin Ting-Chi	0.81%	NA
	Jhan Mao Enterprise Co., Ltd	0.75%	NA

iii.Necessity of Conducting a Private Placement：

(i) Reason for Not Using a Public Offering：Taking into account the conditions of the capital market, timeliness, convenience, and cost-effectiveness of capital raising, the Company proposes to raise funds through a private placement at an appropriate time with specific investors. This approach is intended to facilitate a prompt injection of required capital.

(ii) Private Placement Quota：The total number of shares to be privately placed shall not exceed 15,000,000 shares and shall be executed in one tranche within one year from the date of the shareholders' resolution.

(iii) Purpose of Funds and Expected Benefits：

Proposed Number of Shares to Be Privately Placed	Use of Proceeds	Expected Benefits
15,000,000	1. To strengthen working capital – Ensuring stable operations and financial flexibility for the Company's ongoing activities. 2. To continue investment in new product development and related clinical trials – Supporting innovation, regulatory approvals, and future revenue growth. 3. To develop new markets – Expanding the Company's international presence and accelerating market penetration.	To accelerate the promotion of the Company's products in domestic and international markets, thereby increasing revenue and profitability.

(3) The rights and obligations of the common shares to be privately placed under this proposal shall, in principle, be the same as those of the Company's existing common shares. However, except for the transferees permitted under Article 43-8 of the Securities and Exchange Act, the privately placed common shares shall not be transferred within three years from the delivery date. After the three-year restriction period, the Company may apply to the competent authority for retroactive public issuance and listing, provided that all relevant regulatory

requirements are met.

(4) The key terms of this proposal, including but not limited to the issue price discount rate, issue price, number of shares to be issued, total amount to be raised, project items, scheduled progress of fund utilization, anticipated benefits, and other related matters, shall be submitted to the shareholders' meeting for authorization of the Board of Directors to determine in light of market conditions and the Company's operational needs. If any amendment or revision is subsequently required by the competent authority or due to operational assessments, changes in objective circumstances, or changes in applicable laws or regulations, the Board of Directors is also authorized to handle such matters in full.

(5) It is proposed that the Chairperson or his/her designated representative be authorized to act on behalf of the Company in signing and negotiating all agreements and documents related to this private placement and to take all necessary actions in connection therewith.

(6) This proposal has been approved by the Audit Committee and resolved by the Board of Directors on February 24, 2026.

(7) Please discuss.

Resolution：

4. Election Item

Subject：Elections of board directors.

(Proposed by the Board of Directors)

Explanation：(1) The Company currently has thirteen directors (including four independent directors). Their term of office will expire on May 17, 2026. In accordance with the Company Act, the directors may continue to perform their duties until the newly elected directors assume office following the comprehensive re-election of directors at the 2026 Annual General Meeting of Shareholders.

(2) Pursuant to Article 17 of the Company’s Articles of Incorporation, eleven directors (including four independent directors) shall be elected at this Annual General Meeting. The election of directors adopts the candidate nomination system, and shareholders shall elect directors from the list of nominees. The newly elected directors shall assume office on the date of election for a three-year term, from June 12, 2026 to June 11, 2029.

(3) The list of candidates for directors and independent directors for this election was approved by the Board of Directors on February 24, 2026. Please refer to Attachment 6 (page 61~66) for Elections of Board Directors.

(4) Please refer to Appendix 3 (page 84-86) for"Rules for Director Elections".

(5) Please conduct the election.

Election resolution：

5. Other Item

Subject：Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business.

(Proposed by the Board of Directors)

Explanation：(1) According to Article 209 of the Company Law, if a director engages in an act within the scope of the company's business for themselves or others, they must explain the important details of their actions to the shareholders' meeting and obtain their approval.

(2) Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business, Please refer to Attachment 7 (page 67) for details on directors and their representatives holding concurrent positions in other companies.It is proposed that the Shareholders' Meeting agree to lift the restrictions on director competition from the date of the newly elected directors' appointment.

(3) This case has been approved by the board of directors on February 24, 2026.

(4) Please discuss.

Resolution：

6. Extemporary Motions

7. Adjournment

III. Attachments

Attachment 1

AmCad BioMed Corporation
The 2025 Business Report

1. Business Philosophy and Implementation Overview

In 2025, the application of artificial intelligence (AI) in medical imaging diagnosis continued to expand. The Company's product, AmCAD-UO®, maintained steady growth in the domestic market. It obtained self-pay medical order codes approved by the Chiayi City and Hsinchu County Health Bureaus and was successfully introduced into multiple medical institutions, including Far Eastern Memorial Hospital and China Medical University Hospital (Hsinchu Branch), further broadening its clinical applications and market penetration. In addition, the Company entered into collaborative research agreements with the Arthur A. Dugoni School of Dentistry at the University of the Pacific and Stanford University to actively explore applications in dentistry. The Company also completed the signing of a distribution agreement and product shipment to its distributor in Turkey, successfully entering a key Middle Eastern market. Furthermore, the patent titled "Method for Predicting the Risk of Sleep Apnea" passed examination and was granted in the United States, further strengthening the Company's intellectual property portfolio.

With respect to thyroid diagnostic products, AmCAD-UT® successfully expanded into the Jordanian market in 2025, with its first overseas customer adopting a handheld ultrasound solution integrated with AmCAD-UT LIVE functionality. In Taiwan, AmCAD-UT® has already been adopted by more than 30 medical institutions. The Company has also applied for a temporary reimbursement program under the National Health Insurance (NHI) system, and the product is expected to be included in NHI coverage in 2026, marking an important milestone in the development of the Company's innovative medical devices.

Looking ahead, as a leading domestic enterprise in AI-based innovative medical devices, the Company will continue to leverage its advanced AI technologies and comprehensive patent portfolio to enhance its AI diagnostic capabilities and promote the clinical application of AmCAD-UT®, AmCAD-UO®, and AmCAD-UB® across diverse medical fields. At the same time, the Company will deepen its global market partnerships and capitalize on its existing AI scanning and real-time imaging analysis technologies, together with handheld ultrasound devices, to accelerate product adoption, clinical integration, international market access, and future growth.

2. Results of Business Plan Implementation

The key operating results for 2025 by product are summarized as follows:

a. AmCAD-UT®

(1) Applied for the National Health Insurance (NHI) temporary reimbursement program; temporary reimbursement is expected to be granted in 2026, which will further enhance

market penetration and benefit public health.

(2) Expanded the platform ecosystem by completing the execution of an NDA with a German platform provider.

(3) Successfully entered the Jordanian market, securing the first overseas customer to adopt a handheld ultrasound solution integrated with AmCAD-UT LIVE functionality.

(4) Officially launched a fully redesigned AmCAD-UT® interface, incorporating enhanced interface optimization and clinical feedback.

b. AmCAD-UO®

(1) Collaborated with the University of the Pacific, Arthur A. Dugoni School of Dentistry, and Stanford University to expand the product's application in the dental market, while continuing post-market clinical studies.

(2) Clinical research results from Switzerland were successfully published in the internationally recognized journal OTO-HNS, further enhancing the product's global academic visibility.

(3) At the World Sleep exhibition, experts endorsed the technology behind AmCAD-UO®.

(4) Completed product shipment to Turkey, successfully entering a key market in the Middle East.

(5) Successfully introduced the product into multiple medical institutions, including Far Eastern Memorial Hospital and China Medical University Hospital (Hsinchu Branch).

(6) Continued clinical collaborations with National Taiwan University Hospital, Chang Gung Memorial Hospital, and Tzu Chi Hospital to enhance the product's clinical value.

3. Budget Execution

In accordance with the "Regulations Governing the Publication of Financial Forecasts by Public Companies," the Company did not publish a financial forecast for 2025. Therefore, this section is not applicable.

4. Financial Expenditures and Profitability Analysis

Unit: NT$ thousand

Project \ Year		2025	2024	Increase (decrease)%
Finance revenue and expenditure	Operating revenue	30,437	53,105	(43)
	Gross profit	10,023	32,934	(70)
	Net Operating loss	(87,955)	(64,664)	-
	Net non-operating income and expenses	16,552	11,788	40
	Net loss after tax	(71,388)	(52,876)	-
Profitability	Return on assets (%)	(10.83)	(8.73)	-
	Return on equity (%)	(11.29)	(9.26)	-
	Profit rate (%)	(234.54)	(99.57)	-
	Loss per share (in NT$)	(0.88)	(0.88)	-

5. Research Development Status

a. 2025 annual research and development expenditure

Year / Project	2025
Operating revenue (A)	30,437 (in thousands)
Research and development expenses (B)	47,111(in thousands)
Total number of employees (C)	58 people
Total R&D personnel (D)	19 people
R&D expenditure ratio B/A	155%
R&D manpower to total manpower D/C	33%

b. 2025 annual research and development results

R&D Achievements
1. AmCAD-UT® – Optimized the AI deep learning model to improve detection accuracy. – Enhanced and refined the NHI version of the UT Windows software. – Completed integration of the new UI/UX Android version. – Completed integration development with handheld ultrasound devices. – Completed AI platform integration development with a German platform provider. 2. AmCAD-UO® – Optimized the deep learning and diagnostic models. – Officially published a paper in the authoritative Swiss journal OTO-HNS. – Continued clinical trials with the Stanford Sleep Center and the University of the Pacific in the United States. – Continued case enrollment and analysis for clinical studies with NTU Dental School, Chang Gung Memorial Hospital, and pediatric clinical research teams. 3. AmCAD-US Acoustic Scattering Tissue Characterization Platform – Accelerated the automated analysis process. 4. AmCAD-UB® – Optimized the AI deep learning model to improve the accuracy and processing speed of real-time scanning. – Enhanced the scanning and reporting system functions of the UB+UT Live version. – Completed development of the UB feature algorithm. – Provided trial use to clinics and integrated the product with clinics' existing systems.
Regulatory and Patent Developments: – The Taiwan patent application for the "Method for Predicting the Risk of Sleep Apnea" was approved. – Obtained the TFDA certificate for the AI/DL version of AmCAD-UT®. – The U.S. patent for the "Method for Predicting the Risk of Sleep Apnea" was approved and the patent certificate was issued. – Obtained the renewed ISO 13485 certificate following successful completion of the audit.

Chairman/General Manager：Lee Yi-Li　　Accounting Supervisor：Danica Dai

Attachment 2

AmCad BioMed Corporation
Audit Committee's Review Report

We have agreed and submitted the Company's 2025 Financial Statements to the board of Directors and obtained the approval of the Board of directors. The Financial Statements have been audited by Ernst & Young Taiwan engaged by the board of directors with an unqualified opinion in the independent auditor's report.

We audited the Company's 2025 Business Report and deficit compensation proposal which have been resolved by the Board of Directors and has concluded that both of them are in accordance with the related regulations. Pursuant to the regulations set forth in Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, a report is submitted as above. Please review.

Sincerely,

AmCad BioMed Corporation 2026 Annual General Meeting of Shareholders

Convener Of Audit Committee：Chang Ching-Tian

February 24, 2026

Attachment 3

AmCad BioMed Corporation

Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and the Underwriter's Evaluation Results on the Reasonableness of Each Expenditure

Explanation：

1. In accordance with the letters issued by the Financial Supervisory Commission (FSC) and Taipei Exchange (TPEx), including FSC Letter No. 105004713 dated March 14, 2016, and FSC Letter No. 1130343354 dated June 7, 2024.

2. Progress of the Sound Business Operation Plan Execution：

   a. Product Development and Business Promotion

      (1) AmCAD-UT® (Thyroid Ultrasound Computer-Aided Detection System)

      This product has obtained market authorization from the U.S. FDA (510(k)), the EU (CE), Taiwan TFDA, and China CFDA, and is actively expanding into international markets. Operations in the EU and the Middle East have been progressively launched, with adoption by high-end clinics in Dubai already underway.

      Domestically, the Company continues to promote a subscription-based sales model, facilitating product deployment across clinical settings while collecting user feedback, and is advancing toward inclusion in the National Health Insurance (NHI) reimbursement scheme. An application is planned for submission to the NHI Administration in Q1 2026, alongside preparation for expert review meetings. Subject to approval, a new NHI reimbursement code could be implemented as early as 2026.

      (2) AmCAD-UO® (Ultrasound Obstructive Sleep Apnea Detection System)

      The product has obtained regulatory approvals from the U.S. FDA (510(k)), the EU (CE), and Taiwan TFDA.

      Domestically, building on existing self-pay medical service codes in Taipei City and New Taipei City, additional approvals were secured in Chiayi City in Q1 2025 and Hsinchu County in Q3 2025, both with a self-pay price of NTD 4,000. The Company is also collaborating with medical institutions on clinical research to further expand clinical applications and market penetration.

      Internationally, the product has been adopted by premium clinics in Dubai and shipped to Turkey. Ongoing research collaboration with the Pacific University School of Dental Hygiene Studies continues, while clinical study results from Switzerland have been successfully published in the internationally recognized journal OTO-HNS, further enhancing the product's global academic visibility.

      (3) AmCAD-CA® (Thyroid Cytology Assessment System)

      This system assists physicians in performing fine-needle aspiration cytology (FNAC) to enhance diagnostic efficiency and accuracy. It will be integrated with the AmCAD-UT®

system to strengthen the overall diagnostic workflow and technological synergy.AmCAD-Color Enhancement

(4)Development of Diagnostic Hardware for Obstructive Sleep Apnea (OSA)

Building on the clinical experience of the first-generation AmCAD-UO, this project aims to develop a next-generation OSA companion diagnostic device. Laser positioning technology is being incorporated to enhance the precision of oral and upper airway structure scanning, with expanded applications targeting pediatric populations.

In Q1 2025, the Head & Neck Laser Alignment Tool continued to be optimized, alongside the integration of a deep learning computing system to strengthen model performance and AI analytical capabilities. Functional planning for appearance inspection, sound volume, and detection latency has been completed, while parameters such as sound pressure and sensing accuracy remain under clinical evaluation. Ongoing patient enrollment is being conducted in collaboration with the Pediatric Otorhinolaryngology Clinics of National Taiwan University Hospital and the Sleep Disorder Clinic of Chang Gung Memorial Hospital. Completion of device design planning is expected in Q4 2026 upon acquisition of sufficient clinical data.

(5)Breast Ultrasound AI Diagnostic System

This product integrates AI-powered real-time image interpretation for intelligent analysis of breast ultrasound imaging.

In Q1 2025, development focused on a high-sensitivity primary screening module, completing the UB Live scanning interface, feature extraction algorithms, and automated reporting module to ensure hardware compatibility and seamless integration into clinical workflows. The product has been made available for trial use at domestic and international medical institutions, with ongoing feedback collection to further optimize functionality.

In Q2 2025, the product was showcased at the American Society of Breast Surgeons Annual Meeting as a reference for pre-clinical application. Clinical evaluation is currently being conducted by breast surgeons recommended by U.S. partners, with subsequent clinical trials being initiated.

(6)Handheld Ultrasound Device Development

To expand the application of AI in lightweight diagnostic devices, the Company adopts a practicality-driven approach, focusing on enhancing the use cases and user experience of handheld ultrasound systems.

In Q1 2025, device validation and physician evaluations were conducted, alongside ongoing UI/UX optimization to improve interface design and workflow efficiency. To strengthen market competitiveness, the Company is also actively exploring collaboration models with leading international brands, aiming to enhance technology integration and brand advancement, expand application opportunities, and accelerate global market deployment.

(7)Cross-Platform Scalable Framework for AmCAD-UT®

This project aims to establish a cross-platform, hardware-scalable software framework for AmCAD-UT® to support integration with hospital PACS and medical AI platforms,

addressing the growing demand for unified deployment of imaging AI applications and strengthening the Company's long-term competitive advantage.

The Company is currently in the process of identifying suitable clinical sites for patient enrollment. Upon completion of contractual agreements, clinical trials will be formally initiated.

b. Revenue and Profitability Performance

Some projects funded through capital increases are still in the research and clinical validation stages and have not yet been fully converted into revenue, resulting in deferred financial outcomes. The Company will continue to advance product commercialization and market introduction. As products enter clinical application and obtain health insurance coverage, revenue and profitability performance are expected to gradually materialize.

3. Progress Report and Evaluation on the Use of Proceeds from the 2015 Second Cash Capital Increases and the 2024 Cash Capital Increase, Including Actual Disbursements and Reasonableness Assessment by the Underwriter：

a. The Second Cash Capital Increase in 2015 (hereinafter referred to as "the Case") was approved by the Financial Supervisory Commission on March 14, 2016, via Letter No. 1050004713. The proceeds raised under this Case were designated for product development projects (hereinafter referred to as "the Project"), with a total planned budget of NT$267.001 million.

Subsequently, the Board of Directors approved a project modification on November 6, 2018, and a further revision on August 9, 2022. The Company has provided an evaluation report addressing：

- the implementation progress before and after the revisions,
- the expected achievement of project benefits, and
- the reasonableness of the use of remaining funds.

(1) Original Project Scope, Schedule, and Expected Benefits

(i) Original Project Scope

1-1 Total Capital Requirement: NT$267,001 thousand.

1-2 Sources of Funds：

(a) The Company planned to raise capital through a cash capital increase by issuing 11,800 thousand common shares, each with a par value of NT$10, at an issue price of NT$30 per share. The total expected proceeds were NT$354,000 thousand.

(b) If the actual issue price per share was adjusted due to market price fluctuations, resulting in a higher fundraising amount, the excess would be allocated to working capital.

1-3 Original Capital Deployment Plan

Unit: NT$ thousand

Project Item	Planned Completion Date	Total Required Capital	Planned Fund Utilization Schedule									
			2016				2017				2018	
			Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2

Product Development	Cytology-Based Thyroid Tumor Identification System	2018Q2	61,475	3,140	5,471	2,261	9,107	6,286	6,627	4,629	8,806	6,490	8,658
	Smart Functional Ultrasound Device	2018Q2	205,526	2,842	31,596	2,342	11,956	29,340	6,378	32,409	23,170	35,248	30,245
	Total		267,001	5,982	37,067	4,603	21,063	35,626	13,005	37,038	31,976	41,738	38,903

Source: Provided by the Company.

(ii)Original Planned Schedule for Fund Utilization

Unit: NT$ thousand

Project Item	Execution Status		Cumulative as of Q3 2018
Cytology-Based Thyroid Tumor Identification System	Amount Utilized	Planned	61,475
		Actual	27,290
	Execution Progress(%)	Planned	100.00
		Actual	44.39
Smart Functional Ultrasound Device	Amount Utilized	Planned	205,526
		Actual	28,335
	Execution Progress(%)	Planned	100.00
		Actual	13.79
Total	Amount Utilized	Planned	267,001
		Actual	55,625
	Execution Progress(%)	Planned	100.00
		Actual	20.83

Source: Provided by the Company.

The fund utilization progress of the company's second cash capital increase in 2015 fell behind schedule. This delay was primarily due to the fundraising being completed later than originally planned—on June 27, 2016—which resulted in postponed procurement of certain hardware equipment. In addition, discussions with academic institutions and partner manufacturers regarding technical development and integration details led to deferred payments. As of the third quarter of 2018, the accumulated amount utilized was NT$55,625 thousand, representing 20.83% of the originally planned execution progress. Upon evaluation, no material irregularities were identified.

(iii)Status of Achievement of Originally Planned Expected Benefits

The Company’s current capital increase plan totals NT$267,001 thousand, primarily allocated to the development of two new products: a thyroid tumor cytology recognition system and an intelligent functional ultrasound device, with respective investments of NT$61,475 thousand and NT$205,526 thousand.

The thyroid tumor cytology recognition system is designed to assist physicians in improving the accuracy of benign and malignant tumor differentiation in conventional fine-needle aspiration cytology through software-based image annotation. Development is scheduled for completion in the first half of 2018, followed by an application for U.S. FDA approval. The product is expected to generate revenue of NT$7,300 thousand in Q2 2020.

The intelligent functional ultrasound device addresses the limitations of existing

ultrasound systems, which lack real-time image interpretation and immediate abnormality alerts. Leveraging the Company's medical imaging and CAD software technologies, and in collaboration with ultrasound hardware manufacturers, this new ultrasound device is under development. Completion is also targeted for the first half of 2018, with subsequent application for U.S. FDA approval, and is expected to generate revenue of NT$100,800 thousand in Q2 2020.

The projected development timeline and anticipated future sales benefits of these products are summarized as follows:

1-1Planned Product Development Timeline

Product	Design Planning	Design Input	Design Output	Design Verification	Preclinical Evaluation	Marketing Approval Application
Cytology-Based Thyroid Tumor Identification System	2015Q2	2016Q1	2016Q4	2017Q2	2018Q2	Q3 2018: U.S. FDA Application Q4 2018: EU Application Q2 2019: Taiwan Registration Application Q3 2019: China Application
Smart Functional Ultrasound	2015Q2	2016Q2	2017Q1	2017Q3	2018Q2	Q3 2018: U.S. FDA Application Q4 2018: EU Application Q2 2019: Taiwan Registration Application Q3 2019: China Application

Source: Provided by the Company.

1-2Expected Potential Benefits of the Cytology-Based Thyroid Tumor Identification System

Unit: Units; NT$ Thousands

Year	Sales Volume		Unit Price		Sales Value		Gross Profit	Operating Profit
	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System		
2020	19	7	200	500	3,800	3,500	6,644	(20,544)
2021	102	23	200	500	20,400	11,500	29,033	9,017
2022	127	37	200	500	25,400	18,500	39,955	24,583
2023	153	51	200	500	30,600	25,500	51,059	37,209
2024	178	66	200	500	35,600	33,000	62,435	49,161

Source: Provided by the Company.

1-3Expected Potential Benefits of the Smart Functional Ultrasound Device

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2020	42	2,400	100,800	60,726	(851)
2021	118	2,400	283,200	170,611	116,163
2022	186	2,400	446,400	268,929	216,746

Source: Provided by the Company.

As of the end of the third quarter of 2018, the product development projects had not yet been completed; therefore, it is not yet necessary to assess the achievement of the projected sales revenue for the Cytology-Based Thyroid Tumor Identification System and the Smart Functional Ultrasound Device.

(2)Capital Plan, Execution Progress, and Expected Benefits Following the Project Amendment Approved by the Board of Directors on August 9, 2022.

(i)Reason for the Project Amendment

Revision of Product Development Items

As of July 2022 (Year 111), the development of the Cytology-Based Identification System had been completed. In order to efficiently utilize the remaining funds, the company proposed reallocating the unused portion originally designated for the Cytology-Based Identification System to support the ongoing product development of the Smart Functional Ultrasound Device.

1-1 Since the purpose of developing the Cytology-Based Identification System is to complement the Anke Thyroid Detection product and assist physicians in diagnosing thyroid conditions, the market strategy is to distribute it in conjunction with the Anke Thyroid Detection system through laboratory channels. Therefore, FDA approval is not required.

1-2 The product development of the Smart Functional Ultrasound Device aims to effectively enhance product value. In addition to its existing rapid diagnostic function for sleep apnea, the device is also being developed for broader applications in companion diagnostics (such as positive airway pressure devices, oral appliances, and surgical resection). The company is currently collaborating with major hospitals and research centers to conduct related clinical validation studies.

(ii)Revised Project Items and Fund Utilization Progress

Unit: NT$ Thousands

Project Item		Planned Completion Date	Total Required Capital	Actual Fund Utilization Progress						Planned Fund Utilization Progress											
				2016	2017	2018	2019	2020	2021	2022				2023				2024			
										Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Product Development	Cytology-Based Thyroid Tumor Identification System	2018Q2	38,681	7,039	10,256	12,565	5,954	952	1,151	313	334	117 (註 2)	-	-	-	-	-	-	-	-	-
	Smart Functional Ultrasound Device	2018Q2	158,562	13,756	13,158	1,421	-	12,596	21,680	4,414	4,764	7,826	10,710	8,007	9,454	9,956	9,816	8,030	9,515	7,956	5,503
Office Building Purchase		2018Q4	61,083	-	-	61,083 (註 1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity Investment in Subsidiaries		2018Q4	27,000	-	-	27,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Amount			285,326	20,795	23,414	102,069	5,954	13,548	22,831	4,727	5,098	7,943	10,710	8,007	9,454	9,956	9,816	8,030	9,515	7,956	5,503

Note 1：Of the total, NT$18,325 thousand was funded with the company's own capital, while the remaining NT$42,758 thousand was covered by the original budget allocated for the product development of the Smart Functional Ultrasound Device.

Note 2：The Cytology-Based Thyroid Tumor Identification System was completed in July 2022.

(iii)Fund Utilization Progress After Project Amendment

Unit: NT$ Thousands

Project Item	Execution Status		Cumulative as of Q1 2025
Cytology-Based Thyroid Tumor Identification System	Amount Utilized	Planned	38,681
		Actual	38,681
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Smart Functional Ultrasound Device	Amount Utilized	Planned	158,562
		Actual	158,562
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Office Building Purchase	Amount Utilized	Planned	61,083
		Actual	61,083
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Equity Investment in Subsidiaries	Amount Utilized	Planned	27,000
		Actual	27,000
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Total	Amount Utilized	Planned	285,326
		Actual	285,326
	Execution Progress(%)	Planned	100.00
		Actual	100.00

Source: Provided by the Company.

The fund utilization progress of the company’s second cash capital increase in 2015 is as follows: the product development of the Cytology-Based Thyroid Tumor Identification System, the purchase of office buildings, and the equity investment in subsidiaries have all been completed. However, as of the first quarter of 2025, the development of the Smart Functional Ultrasound Device has experienced delays.

The delay is mainly attributed to intensified competition in the target application market of the end product, which led hardware manufacturers to propose integrating various CAD software technologies with hardware devices. Additionally, during the pandemic, certain FDA application processes for CAD software were delayed due to slower case acceptance, which further hindered development progress.

Nonetheless, as of the date of this evaluation, the company has completed the development of the Smart Functional Ultrasound Device and has secured sales orders. The company also plans to continue investing in related R&D efforts to further enhance the functionality of the product.

Overall, the Company has utilized a cumulative amount of NT$285,326 thousand under this plan as of Q3 2025, achieving an actual execution progress of 100.00%, with no material deviations identified.

(iv)Expected Benefits After the Amendment

1-1 Product Development

(a) Planned Product Development Timeline

Product	Design Verification	Clinical Enrollment	Publication	Marketing
Smart Functional Ultrasound	Ongoing Function Optimization	OSA Evaluation / Companion Therapy Enrollment Ongoing	In Progress	FDA Application for Sleep Apnea Assessment Completed in 2024

Note: Due to the limited market potential of the MSK project, the company shifted its focus to the OSA (Obstructive Sleep Apnea) diagnostic field, in which it has already achieved notable results. Considering the business opportunities associated with companion therapies, the company is continuing with related clinical case collection.

(b) Expected Potential Benefits of the Cytology-Based Thyroid Tumor Identification System

Unit: Sets; NT$ Thousands

Year	Sales Volume		Unit Price		Sales Value		Gross Profit	Operating Profit
	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System		
2023	8	3	100	250	800	750	1,488	37
2024	19	8	100	250	1,900	2,000	3,769	2,562
2025	31	11	100	250	3,100	2,750	5,687	3,981
2026	45	17	100	250	4,500	4,250	8,491	6,243
2027	47	19	100	250	4,700	4,750	9,159	6,353
2028	50	22	100	250	5,000	5,550	10,218	7,094

Source: Provided by the Company.

(c) Expected Potential Benefits of the Smart Functional Ultrasound Device

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2023	10	2,000	20,000	12,510	5,417
2024	23	2,400	55,200	38,788	26,096
2025	40	2,400	96,000	69,405	48,363
2026	48	2,400	115,200	84,093	58,491

Source: Provided by the Company.

1-2 Purchase of Office Building

Following the approval of the project amendment by the Board of Directors on November 6, 2018, the company purchased an office unit on the third floor of the same building as the AmCad Biomed Corp. office on Fuxing North Road for NT$61,083 thousand on December 6. The total area of the purchased office is approximately 77.32 pings. Based on the market rental rate of approximately NT$1,800 per ping per month—referencing the rental income received by PhytoHealth Corp., the parent company of AmCad Biomed Corp., for the eighth floor of the same building—it is estimated that the company can save approximately NT$1,670 thousand in annual rental expenses.

After deducting the estimated annual depreciation expense of NT$204 thousand associated with the acquired office property, the net annual benefit starting from 2019 is projected to be approximately NT$1,466 thousand. This benefit is in line with expectations.

Unit: Units; NT$ Thousands

	From 2019 Onward
Expected Annual Rent Savings (Note 1)	1,670
Building Depreciation Cost (Note 2)	(204)
Total	1,466

Source: Provided by the Company.

Note 1：The estimated annual rental savings are calculated based on the prevailing rental rates in the intended purchase area and the planned office space area.

Note 2：The total purchase price of the property (including transfer and related acquisition costs) is estimated at NT$8,142 thousand. Based on a 40-year amortization schedule, the annual depreciation amount is NT$204 thousand (NT$8,142 thousand ÷ 40 years).

1-3 Equity Investment in Subsidiaries

Unit: Units; NT$ Thousands

	2018	2019	2020	2021	2022
Operating Revenue	49,000	119,640	161,430	204,870	250,470
Gross Profit	24,850	69,358	93,183	118,407	144,927
Operating Profit	11,314	21,058	42,783	62,607	83,727
Net Income for the Period	11,314	21,058	34,226	50,086	66,982
Investment Ratio	40.54%	40.00%	40.00%	40.00%	40.00%
Recognized Investment Income for the Year	4,587	8,423	13,690	20,034	26,793
Cumulative Recognized Investment Income	4,587	13,010	26,700	46,734	73,527
Estimated Payback Period	3.01Years				

Broadsound Corp. is a comprehensive ultrasound equipment company and the only manufacturer in the world certified for ultrasound-compatible alternative probes. The company possesses advanced and mature ultrasound technologies, and it is capable of independent research and development, design, manufacturing, global marketing, and after-sales services.

Its core product—ultrasound probes—is the only high-end alternative probe globally that has obtained both U.S. FDA marketing approval and EU CE certification. According to the projected income statement prepared by Broadsound Corp., the accumulated profit is estimated to reach NT$46,734 thousand by 2021, with a projected payback period of approximately 3.01 years.

(3) Assessment of the Variance Between Expected Benefits and Actual Results

(i) Product Development

As of the end of December 2022, the thyroid tumor cytology recognition system had just been completed. While the Company originally anticipated generating revenue starting in 2023, it has since adjusted its strategy to enhance market demand and product competitiveness by integrating the system with the AmCAD-UT® product for joint commercialization. The Company has engaged with leading domestic hospitals, and revenue was generated in 2024.

In addition, the intelligent functional ultrasound device has entered into distribution agreements with overseas agents and generated revenue of NT$3,317 thousand in 2025. The variance from initial projections is primarily attributable to the thyroid tumor

cytology recognition system being an innovative medical device, which requires substantial clinical data and research evidence to influence physician adoption.

Meanwhile, the Company is actively conducting collaborative research with the University of the Pacific School of Dentistry, the Stanford Sleep Medicine Center, and clinical teams in Switzerland to validate the effectiveness of screening and therapeutic applications, thereby enhancing product value. The Company is also actively expanding its presence across international markets, including the United States, Europe, South America, and the Middle East. Recently, a new patent has been granted in the United States, and reimbursement coverage using insurance codes is expected to be initiated at Stanford in the near future.

Based on the evaluation, no material anomalies have been identified.

(ii)Purchase of Office Building

In 2018, the company purchased a 77.32-ping office unit in an industrial-commercial building. Based on the market rental rate of approximately NT$1,800 per ping per month—referencing the rental income received by PhytoHealth Corp., the parent company of AmCad Biomed Corp., for the eighth floor of the same building—the company is estimated to save around NT$1,670 thousand in rental expenses annually.After deducting the annual depreciation expense of NT$204 thousand related to the purchased property, the net annual benefit starting from 2019 is projected to be approximately NT$1,466 thousand. Upon evaluation, this benefit is deemed reasonable.

Unit: Units; NT$ Thousands

	From 2019 and Beyond
Expected Annual Rent Savings (Note 1)	1,670
Building Depreciation Cost (Note 2)	(204)
Total	1,466

Source: Provided by the Company.

Note 1: The estimated annual rental savings are calculated based on prevailing rental rates in the intended purchase area and the purchased floor area.

Note 2: The total purchase price of the property (including transfer and related acquisition costs) is approximately NT$8,142 thousand. Based on a 40-year amortization schedule, the annual depreciation amount is NT$204 thousand (NT$8,142 thousand ÷ 40 years).

(iii)Equity Investment in Subsidiaries

Broadsound Corp. is a comprehensive ultrasound equipment company and the only manufacturer globally certified for ultrasound-compatible replacement probes. It possesses advanced and mature ultrasound technologies, encompassing in-house R&D, design, manufacturing, global marketing, and aftermarket services.

Its flagship product, ultrasound probes, represents the only high-end replacement probes worldwide that have obtained both U.S. FDA market clearance and EU CE certification.

According to Broadsound Corp.’s self-prepared financial statements for Q3 2025, the Company reported a net loss after tax of NT$17,217 thousand, primarily due to ongoing order negotiations with key customers.

(4)Reasonableness of the Use of Unutilized Funds

The Company has fully utilized the allocated expenditures for product development, with no material anomalies identified upon evaluation.

(5)Whether the Project Involves Any Changes

The second cash capital increase plan in 2015 was amended with approval from the Board of Directors on August 9, 2022. The main purpose of the amendment was to reallocate the unutilized funds—amounting to NT$22,794 thousand—from the completed development of the Cytology-Based Thyroid Identification System to the ongoing development of the Smart Functional Ultrasound Device.Since the reallocated amount accounts for 6.44% of the total raised funds of NT$354,000 thousand, which is below the 20% threshold, it does not constitute a material change to the plan. Nevertheless, the revised fund execution schedule, the intended use of unutilized funds, and the achievement status of expected benefits have been reviewed by the underwriter and are deemed reasonable, with no material irregularities identified.

b.The Company's 2024 capital increase through issuance of new shares (the "Offering") was conducted in accordance with Article 9, Paragraph 1, Subparagraph 7 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, as well as the Financial Supervisory Commission's letter No. Jin-Guan-Zheng-Fa-1130343354 dated June 7, 2024.As the underwriter, we have provided an assessment of AmCad BioMed Corporation's (the "Company" or "AmCad BioMed") progress in the utilization of proceeds from the 2024 capital increase, the achievement of expected benefits, and the reasonableness of the use of any unutilized funds.

(1)Project Overview, Progress, and Expected Benefits

(i)Total Offering Amount: The Company issued 10,000 thousand new shares through a cash capital increase, with a par value of NT$10 per share and an issue price of NT$23 per share (at a premium), resulting in total proceeds of NT$230,000 thousand.

(ii)Use of Proceeds: Product development.

(iii)Project Items and Expected Implementation Schedule:

Unit: Units; NT$ Thousands

Project Item	Planned Completion Date	Total Required Capital	Planned Fund Utilization Schedule											
			2024		2025				2026				2027	
			Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Companion Diagnostic Hardware Development for Sleep Apnea	2026Q3	99,760	-	28,920	720	28,920	720	19,520	720	720	19,520	-	-	-
Breast Ultrasound Clinical Research	2027Q2	104,000	14,157	6,757	7,407	7,407	7,531	7,407	7,407	7,407	7,531	7,407	7,057	16,525
Handheld Ultrasound Device Development	2025Q3	37,920	2,400	17,880	1,680	480	15,480	-	-	-	-	-	-	-
Total		241,680	16,557	53,557	9,807	36,807	23,731	26,927	8,127	8,127	27,051	7,407	7,057	16,525

Source: Provided by the Company.

(iv)Expected Benefits:

A. Development of Companion Diagnostic Hardware for Sleep Apnea

Building on its experience with the first-generation sleep apnea detection device and related software, the Company plans to integrate AmCAD-UO with a next-generation companion diagnostic device for sleep apnea. By enhancing the laser positioning instrument, the new device is expected to provide wider-angle and more precise scanning of relevant oral structures, while also expanding its target user base to the pediatric market. The next-generation companion diagnostic hardware will be adjustable for pediatric patients.

Product design planning is scheduled for Q4 2024, with completion of product design expected in Q3 2026, followed by an application for U.S. FDA market clearance in Q4 2026. After obtaining market clearance in 2027, the product is expected to commence sales.

Projected operating revenue for 2027–2030 is estimated at a total of NT$352,656 thousand, with total operating net profit expected to reach NT$171,044 thousand.

Product	Design Planning	Design Input	Design Output	Design Verification	Marketing Approval Application
Companion Diagnostic Hardware for Sleep Apnea	2024Q4	2025Q2	2025Q4	2026Q3	2026Q4

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2027	8	2,232	17,856	12,736	8,660
2028	30	2,232	66,960	47,760	32,477
2029	50	2,232	111,600	79,600	54,128
2030	70	2,232	156,240	111,440	75,779
Total	158	2,232	352,656	251,536	171,044

Source: Provided by the Company.

B. Breast Ultrasound Clinical Research

The breast ultrasound software is an intelligent diagnostic system for real-time breast cancer detection, which, when paired with ultrasound hardware, enables its key feature of immediate detection. To expand product opportunities overseas, the plan includes clinical trials for FDA approval in both domestic markets and the U.S., a major market for this technology. Clinical trials are expected to be completed in the second quarter of 2027, with the U.S. FDA submission scheduled for the third quarter of 2027 .Currently, a major international ultrasound manufacturer is in discussions with the company regarding collaboration on the Anke Thyroid Detection product and has also expressed interest in the breast ultrasound software. After obtaining FDA approval in the second quarter of 2028, the company plans to partner with the international ultrasound manufacturer to integrate the breast cancer ultrasound

software into their existing ultrasound devices.From 2028 to 2032, the company expects to receive a total of NT$119,700 thousand in sales royalties.

Product	R&D Progress After Capital Injection	Planned Clinical Trial	Expected Start Date	Planned Completion Date of Fund Utilization	Marketing Approval Application
Breast Ultrasound	FDA Application for Breast Ultrasound	Breast Ultrasound Clinical Trial (Note 1)	2024Q3	2027Q2	2027Q3

Note: The breast ultrasound clinical trials will be conducted in both the United States and Taiwan, with an expected enrollment of 400 subjects in Taiwan and 800 subjects in the U.S. This fundraising project is scheduled to run through the second quarter of 2027, at which time the clinical trial reports will be submitted to the respective authorities in Taiwan and the U.S. for marketing approval applications.

Unit: Units; NT$ Thousands

Year	2028	2029	2030	2031	2032	2033	Total
License Volume	24	27	30	30	30	30	171
License Unit Price	700	700	700	700	700	700	700
Sales Revenue Share	16,800	18,900	21,000	21,000	21,000	21,000	119,700

Source: Provided by the Company.

C. Development of Handheld Ultrasound Device

The handheld ultrasound device integrates artificial intelligence into a portable ultrasound system, enhancing user convenience as well as diagnostic accuracy and efficiency. This application is particularly beneficial for patients in remote and rural areas.Under the current project timeline, product design planning is scheduled for the fourth quarter of 2024, with design completion expected in the third quarter of 2025. The company plans to submit an application for U.S. FDA marketing approval in the fourth quarter of 2025, and commence sales upon receiving the marketing authorization in 2026. From 2026 to 2028, the projected total revenue is NT$109,500 thousand, with a total projected operating profit of NT$44,676 thousand.

Product Development Timeline	Design Planning	Design Input	Design Output	Design Verification	Marketing Approval Application
Handheld Ultrasound Device	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2026	230	150	34,500	20,700	14,076
2027	240	150	36,000	21,600	14,688
2029	260	150	39,000	23,400	15,912
Total	730	450	109,500	65,700	44,676

Source: Provided by the Company.

(2)Status of Original Fund Utilization and Achievement of Expected Benefits

(i) Fund Utilization Progress as of Q3 2025

Unit: Units; NT$ Thousands

Project Item	Execution Status		2025Q3	Cumulative as of Q3 2025	Reasons for Progress Ahead of or Behind Schedule and Improvement Plan
Development of Companion Diagnostic Hardware for Sleep Apnea	Amount Utilized	Planned	720	59,280	Development of Companion Diagnostic Hardware for Sleep Apnea:Functional planning for appearance inspection, sound volume, and detection latency has been completed. However, user feedback-related functions, as well as parameters such as sound pressure and sensing accuracy, remain subject to clinical validation. The Company continues to collaborate with the Pediatric Otorhinolaryngology Department of National Taiwan University Hospital and the Sleep Medicine Center at Chang Gung Memorial Hospital to conduct patient enrollment and better understand clinical needs. Completion of hardware design planning is expected in Q2 2026 upon acquisition of clinical data. Clinical Study of Breast Ultrasound: The originally designated clinical research organization was found to have costs significantly exceeding the Company's expectations. Considering budget constraints, the Company plans to engage an alternative suitable clinical research organization, resulting in project delays. The product was presented at the American Society of Breast Surgeons Annual Meeting in Q2 2025 as a reference for pre-clinical evaluation. Current clinical evaluation is primarily conducted by breast surgeons recommended by U.S. partner ultrasound system providers. Following completion of evaluation in Q3 2026, the Company plans to finalize agreements and proceed with subsequent clinical trials. Development of Handheld Ultrasound Device: Adopting a practicality-driven approach, the Company continues to enhance application scenarios and user experience for handheld ultrasound devices. While FDA submission was originally planned for Q4 2025, development has been delayed due to ongoing UI/UX optimization aimed at improving interface design and workflow efficiency. The Company will accelerate development and proceed with integration into handheld ultrasound systems. Subsequent plans include exploring collaborations with leading international brands upon completion of system development to expand application opportunities and accelerate global market deployment.
		Actual	4,023	6,237	
	Execution Progress (%)	Planned	0.72	59.42	
		Actual	4.03	6.25	
Clinical Study of Breast Ultrasound	Amount Utilized	Planned	7,531	43,259	
		Actual	910	1,926	
	Execution Progress (%)	Planned	7.24	41.60	
		Actual	0.88	1.85	
Development of Handheld Ultrasound Device	Amount Utilized	Planned	15,480	37,920	
		Actual	1,928	5,281	
	Execution Progress (%)	Planned	40.82	100.00	
		Actual	5.08	13.93	
Total	Amount Utilized	Planned	23,731	140,459	
		Actual	6,861	13,444	
	Execution Progress (%)	Planned	9.82	58.12	
		Actual	2.84	5.56	

Source: Provided by the Company.

(ii)Achievement of Originally Expected Benefits

As of the end of Q3 2025, the product development projects have not yet been completed. Therefore, it is not yet necessary to assess the projected sales revenue of the sleep apnea companion diagnostic hardware and handheld ultrasound device, nor the achievement of revenue-sharing from breast ultrasound sales.

(iii)Revised Funding Plan, Implementation Progress, and Expected Benefits Approved by the Board on November 6, 2025

A. Reason for Plan Revision

a. The breast ultrasound clinical study focuses on the detection, quantification, and visualization of BI-RADS ultrasound features of breast tumors. By leveraging multicenter cases and establishing gold-standard validation through expert consensus, the study aims to demonstrate product value while effectively optimizing clinical research costs.
b. To further enhance development efficiency, a portion of the budget originally allocated to the breast ultrasound clinical study has been reallocated to establish a cross-platform, hardware-scalable software framework for AmCAD-UT®. This initiative aims to support integration with hospital PACS and medical AI platforms for various imaging AI applications, thereby capturing market opportunities and enhancing revenue and profitability.

B. Revised Project Items and Fund Utilization Progress

Unit: NT$ thousand

Project Item	Total Required Funding Amount	Actual Fund Utilization Progress	Planned Fund Utilization Progress															
		2024	2025				2026				2027				2028			
			Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Development of Companion Diagnostic Hardware for Sleep Apnea	99,760	360	841	1,013	4,023	6,100	4,600	5,100	6,000	5,100	4,600	4,600	4,600	4,600	12,000	12,000	12,000	12,223
Clinical Study of Breast Ultrasound	59,000	476	260	280	910	3,300	3,000	3,000	2,700	4,000	2,700	2,700	2,700	2,700	7,500	7,500	7,500	7,774
Development of Handheld Ultrasound Device	37,920	300	767	2,286	1,928	3,000	2,000	2,000	2,000	1,700	1,700	1,700	1,700	1,700	3,700	3,800	3,800	3,839
Cross-Platform Scalable Framework for AmCAD-UT®	45,000	-	-	-	-	-	4,000	4,000	4,000	4,000	4,000	4,000	4,000	4,000	3,250	3,250	3,250	3,250
Total	241,680	1,136	1,868	3,579	6,861	12,400	13,600	14,100	14,700	14,800	13,000	13,000	13,000	13,000	26,450	26,550	26,550	27,086

Source: Provided by the Company.

C. Revised Expected Benefits

a. Development of Companion Diagnostic Hardware for Sleep Apnea

Due to the need for continuous adjustments based on user feedback, as well as optimization of sound pressure and sensing accuracy, the development progress of the sleep apnea companion diagnostic hardware has been slower than originally expected.

Product design is now anticipated to be completed in Q4 2026, followed by an application for U.S. FDA market clearance in 2027. Sales are expected to commence after obtaining regulatory approval in 2028.

Assuming market conditions remain unchanged, the realization of expected benefits will be deferred to post-2028, while the overall estimated benefit amount remains unchanged.

Product	Design Planning	Design Input	Design Output	Design Verification	Regulatory Submission
Sleep Apnea Companion Diagnostic Hardware	2024Q4	2025Q2	2026Q4	2027Q4	2028Q4

Unit: Units; NT$ thousand

Year	Sales Volume	Unit Price	Sales Revenue	Gross Profit	Operating Net Profit
2028	8	2,232	17,856	12,736	8,660
2029	30	2,232	66,960	47,760	32,477
2030	50	2,232	111,600	79,600	54,128
2031	70	2,232	156,240	111,440	75,779
Total	158	2,232	352,656	251,536	171,044

Source: Provided by the Company.

b. Clinical Study of Breast Ultrasound

Due to the originally designated clinical research organization having costs significantly exceeding expectations, the progress of the breast ultrasound clinical study has been slower than planned.

The Company will instead adopt a multicenter approach and establish gold-standard validation through expert consensus to demonstrate product effectiveness, highlight its unique features, and effectively optimize clinical research costs. Clinical studies across multiple countries are expected to be completed in Q2 2028, followed by an application for U.S. FDA market clearance in Q4 2028.

Assuming market conditions remain unchanged, the realization of expected benefits will be deferred to post-2029, while the overall estimated benefit amount remains unchanged.

Product	R&D Progress After Capital Injection	Planned Clinical Trials	Expected Start Time	Expected Completion Time of Fund Utilization	Regulatory Submission
Breast Ultrasound	FDA Submission for Breast Ultrasound	Breast Ultrasound Clinical Trial (Note)	2024Q3	2028Q4	2028Q4

Note: Clinical trials for breast ultrasound will be conducted in both the United States and Taiwan, with planned enrollment of 800 and 400 subjects, respectively. The fundraising plan is expected to be executed through Q4 2028, at which time clinical study reports will be submitted to regulatory authorities in both Taiwan and the United States for market approval applications.

Unit: Units; NT$ thousand

Year	2029	2030	2031	2032	2033	2034	Total
Number of Licenses	24	27	30	30	30	30	171
License Fee per Unit	700	700	700	700	700	700	700
Revenue from Profit Sharing	16,800	18,900	21,000	21,000	21,000	21,000	119,700

Source: Provided by the Company.

c. Development of Handheld Ultrasound Device

Due to ongoing UI/UX optimization to enhance the user interface and workflow design, the development of the handheld ultrasound device has been delayed. Design verification is now expected to be completed in Q4 2027, followed by an application for U.S. FDA market clearance in 2028.

Assuming market conditions remain unchanged, the realization of expected benefits will be deferred to post-2029, while the overall estimated benefit amount remains unchanged.

Product	R&D Progress After Capital Injection	Planned Clinical Trials	Expected Start Time	Expected Completion Time of Fund Utilization	Regulatory Submission
Handheld Ultrasound Device	2024Q4	2025Q1	2025Q3	2027Q4	2028Q4

Unit: Units; NT$ thousand

Year	Sales Volume	Unit Price	Sales Revenue	Gross Profit	Operating Net Profit
2029	230	150	34,500	20,700	14,076
2030	240	150	36,000	21,600	14,688
2031	260	150	39,000	23,400	15,912
Total	730	450	109,500	65,700	44,676

Source: Provided by the Company.

d. Cross-Platform Scalable Framework for AmCAD-UT®

This project aims to establish a cross-platform, hardware-scalable software framework for AmCAD-UT® to support integration with hospital PACS and medical AI platforms for various imaging AI applications.

The project timeline includes planned inclusion in the National Health Insurance (NHI) system in Q1 2026, followed by real-world evidence (RWE) clinical data collection as required by NHI, with completion expected in Q4 2028.

Projected total operating revenue for 2029–2031 is estimated at NT$120,000 thousand, with total operating net profit expected to reach NT$77,928 thousand.

Product	R&D Progress After Capital Injection	Planned Clinical Trials	Expected Start Time	Expected Completion Time of Fund Utilization
Cross-Platform Scalable Framework for AmCAD-UT®	Integration of various imaging AI applications through hospital PACS or medical AI platforms	Clinical enrollment for NHI-required real-world evidence	2026Q1	2028Q4

Unit: Units; NT$ thousand

Year	Sales Volume	Unit Price	Sales Revenue	Gross Profit	Operating Net Profit
2029	40,000	1	40,000	38,200	25,976
2030	40,000	1	40,000	38,200	25,976
2031	40,000	1	40,000	38,200	25,976
Total	120,000	3	120,000	114,600	77,928

Source: Provided by the Company.

D. Fund Utilization Progress After Plan Revision

a. Fund Utilization Progress as of Q1 2026

Unit: NT$ thousand

Project Item	Execution Status		2026Q1	Cumulative as of Q1 2026	Reasons for Progress Ahead of or Behind Schedule and Improvement Plan
Development of Companion Diagnostic Hardware for Sleep Apnea	Amount Utilized	Planned	4,600	16,937	Development of Companion Diagnostic Hardware for Sleep Apnea:Functional planning for appearance inspection, sound volume, and detection latency has been completed. However, user feedback-related functions, as well as parameters such as sound pressure and sensing accuracy, remain subject to clinical validation. The Company continues to collaborate with the Pediatric Otorhinolaryngology Department of National Taiwan University Hospital and the Sleep Medicine Center at Chang Gung Memorial Hospital to conduct patient enrollment and better understand clinical needs. Completion of hardware design planning is expected in Q2 2026 upon acquisition of clinical data. Clinical Study of Breast Ultrasound:The Company is focusing on the detection, quantification, and visualization of BI-RADS ultrasound features of breast tumors. By leveraging multicenter cases and establishing gold-standard validation through expert consensus, the study aims to demonstrate product value while optimizing clinical research costs. Current clinical evaluation is primarily conducted by breast surgeons recommended by U.S. partner ultrasound system providers. Evaluation is expected to be completed in Q3 2026, followed by contract finalization and subsequent clinical trials. The Company also plans to reallocate approximately NT$45,000 thousand in cost savings to support clinical studies for the AmCAD-UT® cross-platform scalable framework. Development of Handheld Ultrasound Device:Adopting a practicality-driven approach, the Company continues to enhance application scenarios and user experience for handheld ultrasound devices. Integration with a new UI/UX design was completed in Q4 2025. The Company is currently in discussions with several partners and plans to showcase the product at exhibitions to assess market response. Cross-Platform Scalable Framework for AmCAD-UT®:Inclusion in the National Health Insurance (NHI) system is targeted for Q3 2026. The Company is currently identifying suitable clinical sites, with clinical trials to commence upon completion of contractual agreements.
		Actual	6,649	21,060	
	Execution Progress (%)	Planned	4.61	16.98	
		Actual	6.66	21.11	
Clinical Study of Breast Ultrasound	Amount Utilized	Planned	3,000	8,226	
		Actual	1,675	5,853	
	Execution Progress (%)	Planned	5.08	13.94	
		Actual	2.84	9.92	
Development of Handheld Ultrasound Device	Amount Utilized	Planned	2,000	10,281	
		Actual	2,180	10,931	
	Execution Progress (%)	Planned	5.27	27.11	
		Actual	5.75	28.83	
Cross-Platform Scalable Framework for AmCAD-UT®	Amount Utilized	Planned	4,000	4,000	
		Actual	1,568	1,568	
	Execution Progress (%)	Planned	8.89	8.89	
		Actual	3.48	3.48	
Total	Amount Utilized	Planned	13,600	39,444	
		Actual	12,072	39,412	
	Execution Progress (%)	Planned	5.63	16.32	
		Actual	5.00	16.31	

Source: Provided by the Company.

b. Achievement of Expected Benefits

As of the end of Q1 2026, the product development projects have not yet been completed. Therefore, it is not yet necessary to assess the projected sales revenue of the sleep apnea companion diagnostic hardware, handheld ultrasound device, and the AmCAD-UT® cross-platform scalable framework, nor the achievement of revenue-sharing from breast ultrasound sales.

(3)Summary of Evaluation Process

(i)Project Implementation Progress

As of the end of Q1 2026, the Company has incurred a cumulative actual expenditure of NT$39,412 thousand, representing an overall execution progress of 16.31%, which is broadly in line with the planned progress of 16.32%, with no significant variance.

For the development of companion diagnostic hardware for sleep apnea, functional planning for appearance inspection, sound volume, and detection latency has been completed. However, user feedback-related functions, as well as sound pressure and sensing accuracy, remain subject to clinical validation. The Company continues to collaborate with the Pediatric Otorhinolaryngology Department of National Taiwan University Hospital and the Sleep Medicine Center at Chang Gung Memorial Hospital for patient enrollment to better understand clinical needs. Completion of hardware design planning is expected in Q2 2026 upon acquisition of clinical data.

For the breast ultrasound clinical study, the Company is focusing on the detection, quantification, and visualization of BI-RADS ultrasound features of breast tumors. By leveraging multicenter cases and establishing gold-standard validation through expert consensus, the study aims to demonstrate product value while optimizing clinical research costs. Current clinical evaluation is primarily conducted by breast surgeons recommended by U.S. partner ultrasound system providers. Evaluation is expected to be completed in Q3 2026, followed by contract finalization and subsequent clinical trials. The Company also plans to reallocate approximately NT$45,000 thousand in cost savings to support clinical studies for the AmCAD-UT® cross-platform scalable framework.

For the development of handheld ultrasound devices, the Company adopts a practicality-driven approach to enhance application scenarios and user experience. Integration with a new UI/UX design was completed in Q4 2025. The Company is currently in discussions with several partners and plans to showcase the product at exhibitions to assess market response.

Regarding the AmCAD-UT® cross-platform scalable framework, inclusion in the National Health Insurance (NHI) system is targeted for Q3 2026. The Company is currently identifying suitable clinical sites, with clinical trials to commence upon completion of contractual agreements.

Based on the evaluation, no material anomalies have been identified.

(ii)Achievement of Expected Benefits

As the Company has not yet completed its product development projects, it is not

necessary at this stage to assess the projected sales revenue of the sleep apnea companion diagnostic hardware, handheld ultrasound device, and the AmCAD-UT® cross-platform scalable framework, nor the achievement of revenue-sharing from breast ultrasound sales.

(iii)Unutilized Funds

The Company has not yet fully utilized the expenditures allocated for product development. Based on a review of the Company's bank passbooks and time deposit records, as of the end of March 2026, the Company's cash and cash equivalents amounted to NT$269,345 thousand, which exceeds the unutilized balance of NT$202,268 thousand from the total funds raised under this plan.

Upon evaluation, the Company's fund utilization progress and the balance of unutilized funds are considered reasonable, with no material anomalies identified.

(iv)Whether the Plan Involves Any Changes

The Company's 2024 capital increase through issuance of new shares was approved and became effective by the Financial Supervisory Commission on June 7, 2024 (Ref. No. Jin-Guan-Zheng-Fa-1130343354).

Although the Company's Board of Directors resolved on November 6, 2025 to adjust the breast ultrasound clinical study by adopting a multicenter approach and establishing gold-standard validation through expert consensus—thereby optimizing clinical research costs—and to reallocate the expected savings of NT$45,000 thousand toward clinical studies for the AmCAD-UT® cross-platform scalable framework to support integration with hospital PACS and medical AI platforms and strengthen long-term competitiveness, the amount of such adjustment (NT$45,000 thousand) does not exceed 20% of the total planned funding (NT$241,680 thousand × 20% = NT$48,336 thousand). Therefore, this does not constitute a material change to the plan.

(v)Evaluation Opinion

The Company's 2024 capital increase through issuance of new shares was approved and became effective by the Financial Supervisory Commission on June 7, 2024 (Ref. No. Jin-Guan-Zheng-Fa-1130343354).

In consideration of enhancing the breast ultrasound clinical study through a multicenter approach and establishing gold-standard validation by expert consensus—thereby highlighting product features and optimizing clinical research costs—the Company resolved at its Board meeting on November 6, 2025 to revise the plan by reallocating the expected savings of NT$45,000 thousand to the development of a cross-platform, hardware-scalable framework for AmCAD-UT®. This adjustment aims to support integration with hospital PACS and medical AI platforms for various imaging AI applications and to strengthen the Company's long-term competitive advantage.

As of the end of Q1 2026, the fund utilization progress and the reasonableness of unutilized funds remain appropriate, with no material anomalies identified.

Attachment 4

AmCad BioMed Corporation
The Comparison Table of Amendments to the Sustainable Development Best Practice Principles

After amendment	Before amendment	Reason for amendment
Article 3： In promoting sustainable development initiatives, the company shall, in its corporate management guidelines and business operations, give due consideration to the rights and interests of stakeholders and, while pursuing sustainable operations and profits, also give due consideration to the environment, society and corporate governance. The company shall, in accordance with the materiality principle, conduct risk assessments of environmental, social and corporate governance issues pertaining to company operations and establish the relevant risk management policy or strategy.	Article 3： In promoting sustainable development initiatives, the company shall, in its corporate management guidelines and business operations, give due consideration to the rights and interests of stakeholders and, while pursuing sustainable operations and profits, also give due consideration to the environment, society and corporate governance.	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies.
Article 15： The company is advised to take into account the effect of business operations on ecological efficiency, promote and advocate the concept of sustainable consumption, and conduct research and development, procurement, production, operations, and services in accordance with the following principles to reduce the impact on the natural environment, biodiversity,and human beings from their business operations: (Omitted) 6.Improve efficiency of products and services. 7. Enhance the conservation of marine and terrestrial biodiversity and ecosystems, promote the sustainable use of resources, and ensure fair and equitable benefits.	Article 15： The company is advised to take into account the effect of business operations on ecological efficiency, promote and advocate the concept of sustainable consumption, and conduct research and development, procurement, production, operations, and services in accordance with the following principles to reduce the impact on the natural environment and human beings from their business operations: (Omitted) 6.Improve efficiency of products and services.	With reference to initiatives such as the United Nations Convention on Biological Diversity, and in consideration of relevant laws and regulations on marine and nature conservation, amendments have been made to enhance the conservation of biodiversity and ecosystems, promote the sustainable use of resources, and ensure fair and reasonable benefits.

After amendment	Before amendment	Reason for amendment
Article 17： The company is advised to assess the current and future potential risks and opportunities that climate change may present to enterprises and to adopt related measures. The company is advised to adopt standards or guidelines generally used in Taiwan and abroad to enforce corporate greenhouse gas inventory and to make disclosures thereof, the scope of which shall include the following: 1. Direct greenhouse gas emissions: emissions from operations that are owned or controlled by the company. 2. Indirect greenhouse gas emissions: emissions resulting from the utilization of energy such as imported electricity, heating, or steam. 3. Other indirect emissions: emissions resulting from corporate activities that are not indirect emissions from energy, but are from other sources of emissions owned or controlled by the company. The company is advised to compile statistics on greenhouse gas emissions, volume of water consumption and total weight of waste and to establish policies for energy conservation, carbon and greenhouse gas reduction, reduction of water consumption or management of other wastes. The company' carbon reduction strategies should include obtaining carbon credits and be promoted accordingly to minimize the impact of their business operations on climate change.	Article 17： The company is advised to assess the current and future potential risks and opportunities that climate change may pose to its current and future operations, and compile statistics on greenhouse gas emissions, water consumption, and the total weight of waste. The company should also establish policies on energy conservation and carbon reduction, greenhouse gas reduction, water conservation, and other waste management measures in order to reduce the impact of its operational activities on climate change.	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies.
Article 21： The company is advised to create an environment conducive to the development of their employees' careers and establish effective training programs to foster career skills. It is advisable for the company to establish placement programs to cultivate future industry talents. The company shall establish and	Article 21： The company is advised to create an environment conducive to the development of their employees' careers and establish effective training programs to foster career skills. The company shall appropriately reflect	To promote industry–academia integration and support students' career development, the company should establish

After amendment	Before amendment	Reason for amendment
implement reasonable employee welfare measures (including remuneration, leave and other welfare etc.) and appropriately reflect the business performance or achievements in the employee remuneration, to ensure the recruitment, retention, and motivation of human resources, and achieve the objective of sustainable operations.	its business performance or achievements in its employee compensation policies to ensure the recruitment, retention, and motivation of human resources, thereby achieving the goal of sustainable operations.	industry–academia collaboration programs to cultivate future talent for the industry.
Article 27-1： The company is advised to dedicate resources to cultural and art activities or the cultural and creative industry constantly through endowments, sponsorships, investments, procurements, strategic cooperation, volunteering technical services of enterprises, or other forms of support, to promote cultural development.	(New)	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies.
Article 31： The Company's Sustainable Development Best Practice Principles shall be implemented after approval by the Board of Directors and shall be reported to the shareholders' meeting. The same procedure shall apply to any amendments. The principles were first established under the title "Corporate Social Responsibility Best Practice Principles" on February 21, 2014. The 1st revision was made on April 24, 2015. The 2nd amendment, which also changed the name to "Sustainable Development Best Practice Principles," was made on February 18, 2022. The 3rd amendment was made on February 24, 2026.	Article 31： The Company's Sustainable Development Best Practice Principles shall be implemented after approval by the Board of Directors and shall be reported to the shareholders' meeting. The same procedure shall apply to any amendments. The principles were first established under the title "Corporate Social Responsibility Best Practice Principles" on February 21, 2014. The 1st revision was made on April 24, 2015. The 2nd amendment, which also changed the name to "Sustainable Development Best Practice Principles," was made on February 18, 2022.	Addition of Amendment Frequency and Date.

Attachment 5

Independent Auditors' Report Translated from Chinese

To AmCad BioMed Corporation

Opinion

We have audited the accompanying consolidated balance sheets of AmCad BioMed Corporation (the "Company") and its subsidiaries as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the years ended December 31, 2025 and 2024, and notes to the consolidated financial statements, including the summary of material accounting policies (together "the consolidated financial statements").

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of December 31, 2025 and 2024, and their consolidated financial performance and cash flows for the years ended December 31, 2025 and 2024, in conformity with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards, International Accounting Standards, Interpretations developed by the International Financial Reporting Interpretations Committee or the former Standing Interpretations Committee as endorsed and became effective by Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company and its subsidiaries in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China (the "Norm"), and we have fulfilled our other ethical responsibilities in accordance with the Norm. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of 2025 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue Recognition

The Company and its subsidiaries recognized operating revenue amounts to NT$30,437 thousand in 2025. The Company's principal activities consist of revenue from medical diagnosis products. The Company and its subsidiaries recognize revenue from when it satisfies a performance obligation and the recognition timing. Therefore, we considered this a key audit matter.

Our audit procedures include but are not limited to understanding the trading manners through walkthrough and to evaluating the appropriateness of the accounting policy related to revenue recognition from the sale of medical diagnosis products and the transactions made from sales by testing the internal control effectiveness determined by management. We confirm that the timing of recognizing revenue is when performance obligations are met by reviewing the terms of transaction. We confirm the correctness of recognizing revenue from sale of medical diagnosis product and the existence of sales revenue by performing transactions' detail testing which includes reviewing vouchers of selected samples and cash receipts record. We check transaction records to confirm the occurrence of the revenue. We perform cutoff testing through periods before and after the balance sheet date by reviewing related documentation of selected samples.

Please refer to Note 4 and 6. (15) for revenue related accounting policies and information.

Impairment of non-financial assets

As of December 31, 2025, the total net amount of property, plant and equipment, right-of-use assets and intangible assets of the Company and its subsidiaries was NT$135,154 thousand, accounted 22% of the consolidated total assets. The Company and its subsidiaries are engaged in medical diagnosis products research and development company. The Company and its subsidiaries are still at loss position in the year of 2025 because the medical products are still at development stage. As of the balance sheet date, the Company and its subsidiaries based on the external and internal sources to assess whether there is any indication of impairment. If there is indication of impairment, the impairment testing for above assets is required. The result of impairment evaluation is significant to the consolidated financial statements. Therefore, we consider impairment assessment as a key audit matter.

We have conducted audit procedures including but not limited to obtaining representation letter; to examing the evaluation of the Company and its subsidiaries made on possibility of impairment and its cash generating unit; to obtaining the information on assessing the recoverable amount and assumptions for the intangible assets regularly impairment with indefinite life. We also examined the historical and other business' financial information to evaluate whether the assumptions such as sales growth rate, gross margin, operating profit margin, and discount rate applied in the cash flow forecast are reasonable and are in conformity. We review the accuracy of the calculation for the amount recoverable. In Note 4 and 5 of consolidated financial statements to assess the appropriateness of the accounting policies and disclosures relating to the impairment of

non-financial assets.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards, International Accounting Standards, Interpretations developed by the International Financial Reporting Interpretations Committee or the former Standing Interpretations Committee as endorsed by Financial Supervisory Commission of the Republic of China and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the ability to continue as a going concern of the Company and its subsidiaries, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company and its subsidiaries or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee or supervisors, are responsible for overseeing the financial reporting process of the Company and its subsidiaries.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or

the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Company and its subsidiaries.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability to continue as a going concern of the Company and its subsidiaries. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company and its subsidiaries to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the accompanying notes, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company and its subsidiaries to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of 2025 consolidated financial statements and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse

consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Others

We have audited and expressed an unqualified opinion on the parent company only financial statements of the Company as of and for the years ended December 31, 2025 and 2024.

/s/ Wang, Yahn-Jyun
/s/ Yu, Chien-Ju
Ernst & Young, Taiwan
February 24, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position and results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice. As the financial statements are the responsibility of the management, Ernst & Young cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

ASSETS	Notes	As of December 31, 2024	As of December 31, 2023
Current assets			
Cash and cash equivalents	4, 6	$24,602	$17,756
Financial assets at fair value through profit and loss, current	4, 6	-	4,000
Financial assets at amortized cost, current	4, 6, 8	346,620	343,950
Accounts receivable, net	4, 6	9,327	20,646
Accounts receivable-related parties, net	4, 6, 7	16	11
Current tax assets	4	22	7
Inventories	4, 6	27,341	30,094
Prepayments		2,037	1,282
Other current assets		31	339
Total current assets		409,996	418,085
Non-current assets			
Financial assets at fair value through other comprehensive income, non-current	4, 6	75,800	125,676
Property, plant and equipment	4, 6	70,520	72,181
Right-of-use assets	4, 6, 7	4,692	10,738
Intangible assets	4, 6	59,942	66,322
Refundable deposits	8	1,753	1,871
Total non-current assets		212,707	276,788
Total assets		$622,703	$694,873

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

LIABILITIES AND EQUITY	Notes	As of December 31, 2025	As of December 31, 2024
Current liabilities			
Contract liabilities, current	4, 6	$458	$514
Accounts payable		1,317	2,736
Other payables	6,7	13,727	15,437
Provision, current	4, 6	674	935
Lease liabilities, current	4, 6, 7	1,313	5,147
Other current liabilities		640	374
Total current liabilities		18,129	25,143
Non-current liabilities			
Lease liabilities, non-current	4, 6, 7	3,437	5,724
Guarantee deposit received		316	288
Total non-current liabilities		3,753	6,012
Total liabilities		21,882	31,155
Equity attributable to the parent company			
Capital			
Common stock	4, 6	633,329	633,329
Capital surplus	4, 6	142,166	141,523
Retained earnings			
Accumulated deficits	6	(253,082)	(199,320)
Other components of equity			
Unrealized gains or losses on financial assets measured at fair value through other comprehensive income		(989)	(6,880)
Total equity attributable to the parent company		521,424	568,652
Non-controlling interests	6	79,397	95,066
Total equity		600,821	663,718
Total liabilities and equity		$622,703	$694,873

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Years Ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)

	Notes	For the Years Ended December 31, 2025	2024
Operating revenue	4, 6, 7	$30,437	$53,105
Operating costs	4, 6, 7	(20,414)	20,171
Gross profit		10,023	32,934
Operating expenses	4, 6, 7		
Sales and marketing expense		(20,173)	(19,704)
General and administrative expense		(30,694)	(34,111)
Research and development expense		(47,111)	(43,783)
Total operating expenses		(97,978)	(97,598)
Operating loss		(87,955)	(64,664)
Non-operating income and expenses			
Interest income	6	5,798	5,282
Other income	4, 6	11,243	6,830
Other gains and losses	4, 6	(401)	(144)
Financial costs	4, 6, 7	(88)	(180)
Total non-operating income and expenses		16,552	11,788
Net loss before income tax		(71,403)	(52,876)
Income tax expense	4, 6	15	-
Net loss		(71,388)	(52,876)
Other comprehensive income (loss)			
Items that will not be reclassified subsequently to profit or loss			
Unrealized gains or losses on financial assets measured at fair value through other comprehensive income	4, 6	7,848	5,116
Total other comprehensive income, net of tax		7,848	5,116
Total comprehensive loss		$(63,540)	$(47,760)
Net loss attributable to:			
Shareholders of the parent		$(55,719)	$(50,577)
Non-controlling interests		(15,669)	(2,299)
		$(71,388)	$(52,876)
Comprehensive loss attributable to:			
Shareholders of the parent		$(47,871)	$(45,461)
Non-controlling interests		(15,669)	(2,299)
		$(63,540)	$(47,760)
Loss per share-basic (in NT$)	6		
Loss per share-basic			
Net loss		$(0.88)	$(0.88)

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the Years Ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

	EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE PARENT							
				Retained earnings	Other components of equity			
	Common stock	Advance receipts for share capital	Capital surplus	Accumulated deficits	Unrealized gains or losses on financial assets measured at fair value through other comprehensive income (loss)	Total equity attributable to shareholders of the parent	Non-controlling interests	Total equity
Balance as of January 1, 2024	$532,564	$742	$8,016	$(148,743)	$(11,996)	$380,583	$97,365	$477,948
Net loss for the year ended December 31, 2024	-	-	-	(50,577)	-	(50,577)	(2,299)	(52,876)
Other comprehensive income, net of tax for the year ended December 31, 2024	-	-	-	-	5,116	5,116	-	5,116
Total comprehensive income (loss)	-	-	-	(50,577)	5,116	(45,461)	(2,299)	(47,760)
Issue of shares	100,000	-	130,000	-	-	230,000	-	230,000
Share-based payment transactions	765	(742)	3,507	-	-	3,530	-	3,530
Balance as of December 31, 2024	$633,329	$-	$141,523	$(199,320)	$(6,880)	$568,652	$95,066	$663,718
Balance as of January 1, 2025	$633,329	$-	$141,523	$(199,320)	$(6,880)	$568,652	$95,066	$663,718
Net loss for the year ended December 31, 2025	-	-	-	(55,719)	-	(55,719)	(15,669)	(71,388)
Other comprehensive income, net of tax for the year ended December 31, 2025	-	-	-	-	7,848	7,848	-	7,848
Total comprehensive income (loss)	-	-	-	(55,719)	7,848	(47,871)	(15,669)	(63,540)
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	-	-	1,957	(1,957)	-	-	-
Share-based payment transactions	-	-	643	-	-	643	-	643
Balance as of December 31, 2025	$633,329	$-	$142,166	$(253,082)	$(989)	$521,424	$79,397	$600,821

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

	For the Years Ended December 31,	
	2025	2024
Cash flows from operating activities :		
Net loss before tax	$(71,403)	$(52,876)
Adjustments		
Depreciation	9,090	10,599
Amortization	6,707	7,684
Interest expense	88	180
Interest revenue	(5,798)	(5,282)
Dividend income	(3,500)	(900)
Share-based payment	643	2,902
Loss on disposal of property, plant and equipment	217	188
Gain on disposal of investments	(459)	(29)
Gain on lease modification	(23)	-
Changes in operating assets and liabilities:		
Accounts receivable, net	11,319	(9,313)
Accounts receivable-related parties, net	(5)	3
Other receivables, net	-	18
Inventories, net	479	(11,610)
Prepayments	(755)	791
Other current assets	308	(174)
Contract liabilities	(56)	(1,540)
Notes payable	-	(113)
Accounts payable	(1,419)	896
Other payables	(1,710)	835
Provision	(261)	(194)
Other current liabilities	266	90
Cash outflow generated from operations	(56,272)	(57,845)
Interest received	5,798	5,282
Dividend received	3,500	900
Interest paid	(88)	(180)
Income tax paid	-	(7)
Net cash used in operating activities	(47,062)	(51,850)
Cash flows from investing activities :		
Acquisition Financial assets at fair value through other comprehensive income, non-current	-	(92,501)
Disposal of financial assets at fair value through other comprehensive income	57,724	-
Acquisition of financial assets measured at mortized cost	(113,800)	(294,390)
Proceeds from disposal of financial assets measured at amortized cost	111,130	203,050
Acquisition of financial assets at fair value through profit and loss, current	(98,243)	(63,700)
Proceeds from disposal of financial assets at fair value through profit and loss, current	102,702	64,729
Acquisition of property, plant and equipment	(373)	(2,722)
Decrease in refundable deposits	118	433
Acquisition of intangible assets	(327)	(327)
Net cash provided by (used in) investing activities	58,931	(185,428)
Cash flows from financing activities :		
Increase in guarantee deposits received	28	-
Cash payment for the principal portion of the lease liabilities	(5,051)	(5,252)
Proceeds from issuing shares	-	230,000
Exercise of employee stock options	-	628
Net cash (used in) provided by financing activities	(5,023)	225,376
Net increase (decrease) in cash and cash equivalents	6,846	(11,902)
Cash and cash equivalents at beginning of period	17,756	29,658
Cash and cash equivalents at end of period	$24,602	$17,756

(The accompanying notes are an integral part of the consolidated financial statements.)

Independent Auditors' Report Translated from Chinese

To AmCad BioMed Corporation

Opinion

We have audited the accompanying parent company only balance sheets of AmCad BioMed Corporation (the "Company") as of December 31, 2024 and 2023, and the related parent company only statements of comprehensive income, changes in equity and cash flows for the years ended December 31, 2024 and 2023, and notes to the parent company only financial statements, including the summary of material accounting policies (together "the Parent company only financial statements").

In our opinion, the parent company only financial statements referred to above present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2024 and 2023, and their parent company only financial performance and cash flows for the years ended December 31, 2024 and 2023, in conformity with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the parent company only Financial Statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China (the "Norm"), and we have fulfilled our other ethical responsibilities in accordance with the Norm. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of 2024 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue Recognition

The Company recognized operating revenue amounts to NT$ 9,129 thousand in 2025. The Company's principal activities consist of revenue from medical diagnosis products. The Company recognizes revenue from medical diagnosis products when it satisfies a performance obligation and the recognition timing. Therefore, we considered this a key audit matter.

Our audit procedures include but are not limited to understanding the trading manners through walkthrough and evaluating the appropriateness of the accounting policy related to revenue recognition from the sale of medical diagnosis products and the transactions made from sales by testing the internal control effectiveness determined by management. We confirm that the timing of recognizing revenue is when performance obligations are met by reviewing the terms of transaction. We confirm the correctness of recognizing revenue from sale of medical diagnosis products and the existence of sales revenue by performing transactions' detail testing which includes reviewing vouchers of selected samples and cash receipts record. We check transaction records to confirm the occurrence of the revenue. We perform cutoff testing through periods before and after the balance sheet date by reviewing related documentation of selected samples.

Please refer to Note 4 and 6. (14) for revenue related accounting policies and information.

Impairment of assets

As of December 31, 2025, the total net amount of investments accounted for under the equity method, property, plant and equipment, right-of-use assets and intangible assets of the Company was NT$165,891 thousand, accounted for 31 % of the total assets. The Company is engaged in medical diagnosis product research and development company. The Company is still at loss position in 2025 because the medical diagnosis products are still at development stage. As of the balance sheet date, the Company based on the external and internal sources to assess whether there is any indication of impairment. If there is indication of impairment, the impairment testing for above assets is required. The result of impairment evaluation is significant to the parent company only financial statements. Therefore, we consider impairment assessment as a key audit matter.

We have conducted audit procedures including but not limited to obtain representation letter; to examine the evaluation of the Company made on possibility of impairment and its cash generating unit; to obtain the information on assessing the recoverable amount and assumptions for the intangible assets regularly impairment with indefinite life. We also examined the historical and other business' financial information to evaluate whether the assumptions such as sales growth rate, gross margin, operating profit margin, and discount rate applied in the cash flow forecast are reasonable and are in conformity. We review the accuracy of the calculation for the amount recoverable. In Note 4 and 5 of parent company only financial statements to assess the appropriateness of the accounting policies and disclosures relating to the impairment of assets.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the ability to continue as a going concern of the Company, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee or supervisors, are responsible for overseeing the financial reporting process of the Company.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Company.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability to continue as a going concern of the Company. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the accompanying notes, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the Company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of 2025 parent company only financial statements and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

/s/ Wang, Yahn-Jyun
/s/ Yu, Chien-Ju
Ernst & Young, Taiwan
February 24, 2026

Notice to Readers
The accompanying parent company only financial statements are intended only to present the parent company only financial position and results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally accepted and applied in the Republic of China.

Accordingly, the accompanying parent company only financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice. As the financial statements are the responsibility of the management, Ernst & Young cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY BALANCE SHEETS

December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

ASSETS	Notes	As of December 31, 2025	As of December 31, 2024
Current assets			
Cash and cash equivalents	4, 6	$15,527	$7,898
Financial assets at fair value through profit and loss, current	4, 6	-	4,000
Financial assets at amortized cost, current	4, 6, 8	273,570	255,370
Accounts receivable, net	4, 6	2,868	5,563
Accounts receivable-related parties, net	4, 6, 7	16	11
Current tax assets	4	22	7
Inventories	4, 6	2,219	4,878
Prepayments		1,250	1,186
Other current assets		13	321
Total current assets		295,485	279,234
Non-current assets			
Financial assets at fair value through other comprehensive income, non-current	4, 6	75,800	125,676
Investments accounted for under the equity method	4, 6	84,432	94,878
Property, plant and equipment	4, 6	65,772	67,285
Right-of-use assets	4, 6, 7	4,327	7,452
Intangible assets	4, 6	11,360	15,290
Refundable deposits	8	742	862
Total non-current assets		242,433	311,443
Total assets		$537,918	$590,677

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY BALANCE SHEETS

December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

LIABILITIES AND EQUITY	Notes	As of December 31, 2025	As of December 31, 2024
Current liabilities			
Contract liabilities, current	4, 6	$-	$-
Accounts payable		1,068	2,397
Other payables	6 ,7	10,098	11,445
Lease liabilities, current	4, 6, 7	939	2,175
Other current liabilities		636	370
Total current liabilities		12,741	16,387
Non-current liabilities			
Contract liabilities, non-current			
Lease liabilities, non-current	4, 6, 7	3,437	5,350
Guarantee deposit received		316	288
Total non-current liabilities		3,753	5,638
Total liabilities		16,494	22,025
Equity			
Capital	4, 6		
Common stock		633,329	633,329
Capital surplus	4, 6	142,166	141,523
Retained earnings	6		
Accumulated deficits		(253,082)	(199,320)
Other components of equity			
Unrealized gains or losses on financial assets measured at fair value through other comprehensive income		(989)	(6,880)
Total equity		521,424	568,652
Total liabilities and equity		$537,918	$590,677

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME

For the Years Ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)

	Notes	For the Years Ended December 31, 2025	2024
Operating revenue	4, 6, 7	$9,129	$11,704
Operating costs	4, 6, 7	(3,457)	(4,398)
Gross profit		5,672	7,306
Operating expenses	4, 6, 7		
Sales and marketing expense		(13,960)	(13,527)
General and administrative expense		(24,120)	(26,784)
Research and development expense		(27,914)	(25,790)
Total operating expenses		(65,994)	(66,101)
Operating loss		(60,322)	(58,795)
Non-operating income and expenses			
Interest income	6	4,262	3,566
Other income	4, 6	11,100	6,556
Other gains and losses	4, 6	(263)	(236)
Financial costs	4, 6, 7	(65)	(136)
Share of profit or loss of subsidiary, associates and joint ventures accounted for using the equity method	4, 6	(10,446)	(1,532)
Total non-operating income and expenses		4,588	8,218
Net loss before income tax		(55,734)	(50,577)
Income tax expense	4, 6	15	-
Net loss		(55,719)	(50,577)
Other comprehensive income (loss)			
Items that will not be reclassified subsequently to profit or loss			
Unrealized gain or losses on financial assets at fair value through other comprehensive income	4, 6	7,848	5,116
Total other comprehensive income, net of tax		7,848	5,116
Total comprehensive loss		$(47,871)	$(45,461)
Earnings (loss) per share-basic (in NT$)			
Loss per share-basic	6		
Net loss		$(0.88)	$(0.88)

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY

For the Years Ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

				Retained earnings	Other components of equity	
	Common stock	Advance receipts for share capital	Capital surplus	Accumulated deficits	Unrealized gains or losses on financial assets measured at fair value through other comprehensive income (loss)	Total equity
Balance as of January 1, 2024	$532,564	$742	$8,016	$(148,743)	$(11,996)	$380,583
Net loss for the year ended December 31, 2024	-	-	-	(50,577)	-	(50,577)
Other comprehensive income, net of tax for the year ended December 31, 2024	-	-	-	-	5,116	5,116
Total comprehensive income (loss)	-	-	-	(50,577)	5,116	(45,461)
Issue of shares	100,000	-	130,000	-	-	230,000
Share-based payment transactions	765	(742)	3,507	-	-	3,530
Balance as of December 31, 2024	$633,329	$-	$141,523	$(199,320)	$(6,880)	$568,652
Balance as of January 1, 2025	$633,329	$-	$141,523	$(199,320)	$(6,880)	$568,652
Net loss for the year ended December 31, 2025	-	-	-	(55,719)	-	(55,719)
Other comprehensive income, net of tax for the year ended December 31, 2025	-	-	-	-	7,848	7,848
Total comprehensive income (loss)	-	-	-	(55,719)	7,848	(47,871)
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	-	-	1,957	(1,957)	-
Share-based payment transactions	-	-	643	-	-	643
Balance as of December 31, 2025	$633,329	$-	$142,166	$(253,082)	$(989)	$521,424

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

	For the Years Ended December 31,	
	2025	2024
Cash flows from operating activities :		
Net loss before tax	$(55,734)	$(50,577)
Adjustments		
Depreciation	4,622	6,317
Amortization	3,930	5,036
Interest expense	65	136
Interest revenue	(4,262)	(3,566)
Dividend income	(3,500)	(900)
Share-based payment	643	2,902
Share of loss of subsidiary, associates and joint ventures accounted for using the equity method	10,446	1,532
Loss on disposal of property, plant and equipment	217	188
Gain on disposal of investments	(459)	(29)
Gain on lease modification	(23)	-
Changes in operating assets and liabilities:		
Accounts receivable, net	2,695	(4,604)
Accounts receivable-related parties, net	(5)	3
Inventories, net	1,664	(5,240)
Prepayments	(64)	427
Other current assets	308	(156)
Contract liabilities	-	(1,501)
Accounts payable	(1,329)	1,423
Other payables	(1,347)	686
Other current liabilities	266	90
Cash outflow generated from operations	(41,867)	(47,833)
Interest received	4,262	3,566
Dividend received	3,500	900
Interest paid	(65)	(136)
Income tax paid	-	(7)
Net cash used in operating activities	(34,170)	(43,510)
Cash flows from investing activities :		
Acquisition Financial assets at fair value through other comprehensive income, non-current	-	(92,501)
Proceeds from disposal of financial assets at fair value through other comprehensive income	57,724	-
Acquisition Financial assets at amortized cost	(55,700)	(254,390)
Proceed from redemption of financial assets measured at amortized cost	37,500	154,080
Acquisition in financial assets fair value through profit and loss, current	(98,243)	(63,700)
Proceeds from disposal of financial assets at fair value through profit and loss, current	102,702	64,729
Acquisition of property, plant and equipment	(253)	(2,550)
Decrease in refundable deposits	120	430
Net cash provided by (used in) investing activities	43,850	(193,902)
Cash flows from financing activities :		
Increase in guarantee deposits received	28	-
Cash payment for the principal portion of the lease liabilities	(2,079)	(2,308)
Proceeds from issuing shares	-	230,000
Exercise of employee stock options	-	628
Net cash (used in) provided by financing activities	(2,051)	228,320
Net increase (decrease) in cash and cash equivalents	7,629	(9,092)
Cash and cash equivalents at beginning of year	7,898	16,990
Cash and cash equivalents at end of year	$15,527	$7,898

(The accompanying notes are an integral part of the parent company only financial statements.)

Attachment 6

AmCad BioMed Corporation
Director and Independent Director Candidates

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
1	Director	Lee Yi-Li	Female	Owner/President Management,Harvard School. MBA, Rutgers University. BBA In Finance, National Taiwan University.	Supervisor, Taiwan Bio Industry Organization Fierce Women in Biopharma, Taiwan 2016. Vice President, International Global Corporate Standard Chartered Bank. Vice President, Credit Agricole Corporate And Investment Bank. Manager, Corporate Banking Group, Citibank, N.A.	Chairman /General Manager,Amcad Biomed Corp. Chairman, Phytohealth Corp. Vice Chairman, Maywufa Company Ltd. Chairman, Broadsound Corp. Director, Maywufa Cosmetics (Shanghai) Co., Ltd. Director, Taiwan Incubator SME Development Corp. Independent Director, Sinyi Realty Inc.	582,327	N.A.
2	Director	Phytohealth Corp., Representative:Lee I-Lin	Female	MBA, Carnegie Mellon University. B.ACC., National Taiwan University.	Product Manager, (Sales And Marketing), Janssen Pharmaceutical Factory Of Johnson & Johnson. Auditor/Risk Assessment Consultant, Deloitte Taiwan. Fierce Women in Biopharma, Taiwan 2025. Ten Outstanding Young Woman of the R.O.C.(2026).	Vice Chairman, Amcad Biomed Corp. Vice Chairman/, General Manager, Phytohealth Corp., Executive Director, Maywufa Company Ltd. Vice Chairman, Broadsound Corp. Supervisor, Maywufa Cosmetics (Shanghai) Co., Ltd. Supervisor,Taiwan Bio Industry Organization.	22,155,049	N.A.
3	Director	Chang King-Jen	Male	Researcher at Memorial Sloan-Kettering Cancer Center, N.Y. (U.S.A.) Ph.D. in Clinical Medicine, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University	Director of the Department of Surgery, National Taiwan University Hospital Superintendent of Taoyuan General Hospital, Department of Health Superintendent of Taichung Cheng Ching Hospital	Director, AmCad BioMed Corp. Director, SynCore Biotechnology Co., Ltd. Supervisor, GeneTex International Corporation. Director, Knowledge Freeway Co., Ltd Development Corporation Honorary Professor of Surgery, College of Medicine, National Taiwan	2,902,000	N.A.

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
						University, and Attending Physician. Chairman of the Breast Cancer Foundation. Independent Director, HONG HO PRECISION TEXTILE CO., LTD.		
4	Director	Maywufa Company Ltd. Representative:Sheu Jin-Chuan	Male	Ph.D. in Clinical Medicine, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University Professor of Internal Medicine, College of Medicine, National Taiwan University	Director of the Department of Internal Medicine, Gastroenterology and Hepatology, National Taiwan University Hospital. Visiting Researcher at the National Cancer Institute, National Institutes of Health, USA	Director, AmCad BioMed Corp. Honorary Professor, College of Medicine, National Taiwan University. Chairman, Liver Disease Prevention & Treatment Research Foundation. Chairman, Taiwan Health Foundation. Chairman, Good Liver Foundation. Director, ASMEDIA TECHNOLOGY INC.	3,994,996	N.A.
5	Director	Phytohealth Corp., Representative: Chen Wal-Ter	Male	Master of Science in Human Nutrition, Columbia University, USA M.D., School of Medicine, China Medical College	Vice President (Acting President) of China Medical University.Director. Director of Beigang Hospital, China Medical University. Outstanding Alumni of China Medical University.	Director, AmCad BioMed Corp. Advisor and Chair Professor of the Department of Medicine, College of Medicine, China Medical University. Consultant for Beigang Hospital and Children's Hospital, China Medical University.	22,155,049	N.A.
6	Director	Phytohealth Corp., Representative: Chiou Shu-Ti	Female	Ph.D. in Epidemiology, National Taiwan University. M.S. in Public Health, National Taiwan University. M.D., Yang-Ming Medical College.	Director-General, Health Promotion Administration, Ministry of Health and Welfare. Director-General, Bureau of Health Promotion, Department of Health. Commissioner, Taipei City Department of Health. Director, Yilan County Health Bureau. Adjunct Associate Professor, School of Medicine, National Yang-Ming University. Chair, Governing Board, International Network of Health Promoting Hospitals.	Director, AmCad BioMed Corp. Chairman, Health and Sustainable Development Foundation. Consultant, Cheng Hsin General Hospital. Global Executive Committee Member of the International Alliance for Health Promotion and Education. Chairperson of the International Age-Friendly Health Care Committee. Associate Editor, Global Health Promotion Journal. Adjunct Professor, College of Medicine,	22,155,049	N.A.

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
					Vice Chair, Governing Board, International Network of Health Promoting Hospitals. Co-Chair, International Health Promotion Accreditation Board. Global Vice President for Training, International Union for Health Promotion and Education. President, Association of Past Ten Outstanding Young Women of the Republic of China. Global Vice President for Partnerships, International Union for Health Promotion and Education. Member, Global Scientific Committee, 23rd World Conference on Health Promotion. Chair, International Committee on Environmentally Friendly Health Care. Consulting Physician, Taoyuan Hospital, Ministry of Health and Welfare. Resident Physician, Department of Family Medicine, Taipei Veterans General Hospital.	National Yang Ming Chiao Tung University.		
7	Director	Maywufa Company Ltd. Representative: Gary T. Tseng	Male	Master's Degree, Graduate Institute of Diplomacy and International Law, National Chengchi University. Completed the Taiwan Leadership Program, Harvard Kennedy School, Harvard University. MBA, College of	Vice Chairman, Taiwan External Trade Development Council (TAITRA). Secretary, Office of the President, Republic of China (Taiwan). Director, Special Affairs Office, Office of the President, Republic of China (Taiwan). Passed the Special Examination for Diplomatic and Consular Personnel,	Director, AmCad BioMed Corporation. Advisor, TTY Biopharm Company Limited. Director, Charlotte Investment & Service Inc. Vice Chairman and General Manager, BlackWood Capital Co., Limited. Chairman, Wisteria Trade Co., Ltd. Director, Great Novel Therapeutics	3,994,996	N.A.

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
				Management, National Taiwan University.	Republic of China (Taiwan). Lecturer, Shih Hsin University.	Biotech & Medicals Corporation. Chairperson, Aijilishi Biotech Co., Ltd. Director, Panion & BF Biotech Inc.		
8	Independent Director	Chang Ching-Tian	Male	Master's Degree, Graduate Institute of Business Administration, Chang Gung University. B.S. in Business Mathematics, Soochow University.	Special Assistant to the President, General Management Office of the Formosa Plastics Group, concurrently General Manager of Formosa Plastics Environmental Technology Corporation. Assistant Vice President, General Management Office of the Formosa Plastics Group, concurrently General Manager of Huaya Campus Management Consultant Corporation. Supervisor, BIOTRUST INTERNATIONAL CORPORATION.	Independent Director, AmCad BioMed Corporation.	0	YES (Note)

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
9	Independent Director	Huang Weng-Foung	Male	Ph.D. in Philosophy (Major in Social and Administrative Pharmacy), University of Minnesota, USA. M.S., University of Minnesota (Major in Pharmaceutical Administration). B.S. in Pharmacy, National Taiwan University.	Associate Professor and Professor, Institute of Health and Welfare Policy, National Yang-Ming University. Director, Bureau of Pharmaceutical Affairs and Food Sanitation, Department of Health, Executive Yuan. Director, Pharmaceutical Affairs Division, Department of Health, Executive Yuan. Deputy Director, Pharmaceutical Affairs Division, Department of Health, Executive Yuan.	Independent Director, AmCad BioMed Corporation. Independent Director, TaiGen Biopharmaceuticals Holdings Limited. Independent Director, EUSOL BIOTECH CO., LTD. Corporate Representative Director, ORIENT PHARMA CO., LTD. Director, Panion & BF Biotech Inc. Director, Bowlin Holding Co., Ltd. (Seychelles). Director, Bowlin Holding Co., Ltd. (Cayman). Director, CHENG FONG CHEMICAL CO., LTD. Senior Advisor, YFY Biotech Management Co., Ltd. Corporate Representative Director, Aadi Biosciences, Inc. Corporate Representative Director, Caravel Oculus INC.	0	NO
10	Independent Director	Li Hsueh-Yu	Male	Bachelor of Medicine, China Medical University.	Vice Chair, International Medical Services, Linkou Chang Gung Memorial Hospital. Director, International Affairs Center, Linkou Chang Gung Memorial Hospital. Chair, Department of Otolaryngology, Linkou Chang Gung Memorial Hospital. Executive Director, Taiwan Society of Otorhinolaryngology. President, Taiwan Society of Sleep Medicine. President, Taiwan Association of Voice Medicine.	Independent Director, AmCad BioMed Corporation. Professor-level Attending Physician, Linkou Chang Gung Memorial Hospital. Professor, School of Medicine, Chang Gung University.	0	NO

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
11	Independent Director	Lin She-Yi	Female	Master's Degree in Pharmacy, Taipei Medical University. B.S. in Pharmacy, Taipei Medical University.	Senior Director, Novartis (Taiwan) Co., Ltd. Honorary Director, NTU EMBA Alumni Foundation. Supervisor, HoneyBear Biosciences, Inc.	Independent Director, AmCad BioMed Corporation. Executive Director and CEO, T.M.U. Pharmacy Foundation For Culture and Education. Supervisor, Shu Rong Co., Ltd. Vice Chairman, HoneyBear Biosciences, Inc. Director of Business Development, SCI PHARMTECH, INC. Director, Taiwan Heart Foundation. Director, NTU EMBA Alumni Foundation.	0	NO

Note : Mr. Chang Ching-Tian, an independent director nominee for the current term, has served as an independent director of the Company for more than three consecutive terms. He has been nominated again in consideration of his expertise in finance, accounting, and business, which meets the Company's needs and enables him to contribute his professional strengths.

Attachment 7

AmCad BioMed Corporation

Details on Directors and their representatives Holding Concurrent Positionsin Other Companies

Position	Name	Positions Concurrently Held In Other Companies At Present
Director	Lee Yi-Li	Vice Chairman, Maywufa Company Ltd.
		Chairman, Phytohealth Corp.
		Chairman, Broadsound Corp.
		Director, Maywufa Cosmetics (Shanghai) Co., Ltd.
Director	Phytohealth Corp., Representative:Lee I-Lin	Executive Director, Maywufa Company Ltd
		Vice Chairman/, General Manager, Phytohealth Corp.
		Vice Chairman, Broadsound Corp.
Director	Chang King-Jen	Director, SynCore Biotechnology Co., Ltd.
Corporate Director	Maywufa Company Ltd.	Corporate Director, Phytohealth Corp.
Director	Maywufa Company Ltd. Representative: Gary T. Tseng	Director, Charlotte Investment & Service Inc.
		Director, Great Novel Therapeutics Biotech & Medicals Corporation.
		Chairperson, Aijilishi Biotech Co., Ltd.
		Director, Panion & BF Biotech Inc.
Independent Director	Huang Weng-Foung	Independent Director, TaiGen Biopharmaceuticals Holdings Limited.
		Independent Director, EUSOL BIOTECH CO., LTD.
		Corporate Representative Director, ORIENT PHARMA CO., LTD.
		Director, Panion & BF Biotech Inc.
		Director, Bowlin Holding Co., Ltd. (Seychelles).
		Director, Bowlin Holding Co., Ltd. (Cayman).
		Director, CHENG FONG CHEMICAL CO., LTD.
		Corporate Representative Director, Aadi Biosciences, Inc.
		Corporate Representative Director, Caravel Oculus INC.
Independent Director	Lin She-Yi	Vice Chairman, HoneyBear Biosciences, Inc.
		Director of Business Development, SCI PHARMTECH, INC.

IV. Appendix
Appendix 1

AmCad BioMed Corporation
Rules of Procedure for Shareholders' Meetings

Article 1 (Basis for Formulation)

These Rules are established pursuant to Article 5 of the Corporate Governance Best-Practice Principles for TWSE/GTSM Listed Companies to establish a sound corporate governance system for the Company's shareholders' meetings, enhance oversight functions, and strengthen managerial efficiency.

Article 2

Unless otherwise provided by law or the Articles of Incorporation, the proceedings of the Company's shareholders' meetings shall be conducted in accordance with these Rules.

Article 3 (Convocation and Notice of Shareholders' Meetings)

Unless otherwise provided by law, the Company's shareholders' meetings shall be convened by the Board of Directors.

Any change in the method of convening the shareholders' meeting must be resolved by the Board of Directors and made no later than the date on which the meeting notice is issued.

The Company shall, at least 30 days before a regular shareholders' meeting or 15 days before an extraordinary shareholders' meeting, submit an electronic file containing the meeting notice, proxy form, and explanations of proposals including matters for acknowledgment, discussion, and election or dismissal of directors to the Market Observation Post System (MOPS).

The shareholders' meeting handbook and supplemental materials shall be submitted electronically to MOPS at least 21 days prior to a regular meeting or 15 days prior to an extraordinary meeting. No later than 15 days prior to the meeting, the Company shall prepare the physical copies of the handbook and supplemental materials, which shall be available for shareholders to consult at any time and shall be displayed at the Company and its shareholder services agent.

On the day of the shareholders' meeting, the handbook and supplemental materials shall be made available to shareholders as follows:

1.For physical meetings: provided at the venue.
2.For hybrid meetings: provided at the venue and uploaded electronically to the virtual meeting platform.
3.For virtual-only meetings: uploaded electronically to the virtual meeting platform.

Notices and announcements shall specify the purpose of the meeting; with the consent of the recipient, such notices may be delivered electronically.

If the meeting agenda includes the election or dismissal of directors, amendments to the Articles of Incorporation, capital reduction, application to terminate public listing, approval of director non-competition, capitalization of earnings or capital reserves, company dissolution,

merger, demerger, or matters under Article 185, Paragraph 1 of the Company Act; Article 26-1 and Article 43-6 of the Securities and Exchange Act; or Articles 56-1 and 60-2 of the Regulations Governing the Offering and Issuance of Securities by Issuers, such matters must be itemized in the notice with explanations and may not be proposed as extraordinary motions.

Where the meeting notice specifies a full re-election of directors and includes the effective date of appointment, the same meeting shall not propose any change to the appointment date by extraordinary motion or any other means after the election.

Shareholders holding 1% or more of the total issued shares may submit one proposal for the regular shareholders' meeting. Proposals in excess of one shall not be included in the agenda.

If a shareholder proposal falls under any of the circumstances listed in Article 172-1, Paragraph 4 of the Company Act, the Board of Directors may exclude it from the agenda.

The Company shall, before the book closure date for the regular shareholders' meeting, announce the acceptance of shareholder proposals, the method (in writing or electronically), place, and period for submission, which shall not be fewer than ten days.

Shareholder proposals shall be limited to 300 words; proposals exceeding the limit will not be included in the agenda. Proposing shareholders must attend the meeting in person or by proxy and participate in the discussion of the proposal.

The Company shall notify shareholders of the results of their proposals prior to the issuance of the meeting notice. Proposals meeting the requirements of this Article shall be included in the agenda; those not included shall be explained by the Board of Directors during the meeting.

Article 4 (Proxy Attendance and Authorization)

A shareholder may issue a proxy using the form printed by the Company for each shareholders' meeting, specifying the scope of authorization and appointing a proxy to attend the meeting on their behalf.

Each shareholder may issue only one proxy form and appoint only one proxy. The proxy form must be delivered to the Company no later than five days before the date of the shareholders' meeting. In case of duplicate submissions, the one received first shall prevail, unless the shareholder explicitly states the revocation of a previous proxy.

If the proxy form has been delivered and the shareholder later wishes to attend the meeting in person or vote in writing or electronically, they must notify the Company in writing at least two days before the meeting to revoke the proxy. If the revocation is not made in time, the proxy shall remain valid and prevail.

If the shareholder intends to attend the meeting via video conferencing after submitting a proxy form, they must notify the Company in writing at least two days before the meeting to revoke the proxy. If not revoked within this period, the proxy's vote shall prevail.

Article 5 (Principles for Determining Meeting Location and Time)

The location for convening the shareholders' meeting shall be at the Company's registered office or at a location convenient for shareholders and suitable for holding the shareholders'

meeting. The meeting shall not begin earlier than 9:00 a.m. or later than 3:00 p.m. The determination of the meeting time and place shall take into full consideration the opinions of independent directors.

If the shareholders' meeting is held virtually, the restriction on physical location shall not apply.

Article 6 (Preparation of Sign-In Materials and Documents)

The meeting notice issued by the Company shall specify the time and place for shareholders, solicitors, and proxy agents (hereinafter collectively referred to as "shareholders") to check in, as well as other relevant instructions.

Check-in shall commence at least 30 minutes before the meeting starts. The check-in area must be clearly marked and staffed with adequate and competent personnel. For virtual meetings, shareholders shall check in via the virtual platform starting at least 30 minutes prior to the meeting; shareholders who complete check-in shall be deemed present in person.

Shareholders shall present attendance cards, sign-in cards, or other proof of identity. The Company shall not arbitrarily require additional documents beyond those specified. Solicitors of proxies must carry identification for verification.

Attending shareholders must submit their sign-in cards in place of signing.

The Company shall distribute the meeting handbook, annual report, attendance card, speech slip, ballots, and other meeting materials to shareholders present at the meeting. In the event of director elections, ballots shall also be provided.

If the shareholder is a government agency or a legal entity, multiple representatives may attend the meeting. If a legal entity is appointed as a proxy, it may designate only one representative to attend.

For virtual meetings, shareholders intending to attend by video must register with the Company at least two days before the meeting.

The Company shall upload the meeting handbook, annual report, and other related documents to the virtual meeting platform at least 30 minutes before the meeting and keep them accessible until the meeting ends.

Article 6-1

When the Company convenes a virtual shareholders' meeting, the meeting notice shall include the following information：

1. The method for shareholders to participate in the virtual meeting and exercise their rights.
2. Contingency measures in the event of natural disasters, incidents, or other force majeure that cause disruptions to the virtual meeting platform or participants, including at minimum：
   (1) The time frame during which the disruption must be resolved, and the date for postponement or continuation if necessary.
   (2) Shareholders who did not register for virtual participation in the original meeting may not attend the postponed or continued meeting.

(3) In hybrid meetings, if the virtual platform fails but a legal quorum is still present excluding virtual participants, the meeting shall continue. Shares represented virtually shall be counted toward the quorum, but such shareholders shall be deemed to have abstained from all proposals.

(4) Measures in the event that all proposals have been resolved but extraordinary motions have not yet been addressed.

3. In virtual-only meetings, appropriate alternative measures must be provided for shareholders who encounter difficulties with virtual participation.

Article 7 (Chairperson and Attendees)

If a shareholders' meeting is convened by the Board of Directors, the Chairperson of the Board shall preside. If the Chairperson is on leave or otherwise unable to perform duties, the Vice Chairperson shall act as proxy. If there is no Vice Chairperson or the Vice Chairperson is also unable to perform duties, the Chairperson shall designate an Executive Director as proxy. If there is no Executive Director, a Director shall be appointed. If the Chairperson does not appoint a proxy, the Executive Directors or Directors shall elect one among themselves.

For meetings convened by the Board, the Chairperson should preside in person. A majority of Directors should attend in person, and at least one member from each functional committee shall be present. Attendance shall be recorded in the meeting minutes.

If the meeting is convened by a convener other than the Board, the convener shall act as Chairperson. If there are multiple conveners, one shall be elected from among them.

The Company may appoint legal counsel, accountants, or relevant personnel to attend the meeting.

Article 8 (Audio/Video Recording of Meeting Process)

The entire proceedings of the shareholders' meeting shall be recorded by audio or video and kept for at least one year. If a shareholder files a lawsuit under Article 189 of the Company Act, the recording shall be kept until the conclusion of litigation.

For virtual meetings, the Company shall record and store data related to shareholder registration, check-in, questions, voting, and ballot counting results. The virtual meeting must be continuously recorded without interruption.

The aforementioned recordings and data must be properly preserved and provided to the entity responsible for managing the virtual meeting system.

Article 9 (Calculation of Shares Present and Commencement of Meeting)

Attendance at a shareholders' meeting shall be based on shares represented. Shares counted include those based on submitted sign-in cards, virtual platform check-ins, and voting rights exercised in writing or electronically.

At the scheduled meeting time, the Chairperson shall announce the start of the meeting and disclose the number of shares with and without voting rights. If shareholders representing more than

half of the total issued shares are not present, the Chairperson may postpone the meeting up to two times, not exceeding one hour in total. If a quorum of one-third is still not reached, the Chairperson shall declare the meeting adjourned. In virtual meetings, the Company shall announce the adjournment on the virtual platform.

If shareholders representing one-third of the total issued shares are present after the second delay, a tentative resolution may be passed per Article 175, Paragraph 1 of the Company Act, and a new meeting shall be convened within one month. Shareholders attending virtually must re-register in accordance with Article 6.

If the number of shares represented exceeds one-half of total issued shares before the end of the meeting, the Chairperson may re-submit the tentative resolution for voting under Article 174 of the Company Act.

Article 10 (Discussion of Proposals)

For meetings convened by the Board of Directors, the agenda shall be set by the Board. Each proposal, including amendments and extraordinary motions, shall be discussed and voted on one by one. The meeting shall proceed according to the predetermined agenda, and changes may only be made by resolution of the shareholders.

If the meeting is convened by someone other than the Board, the same rule applies.

Before the agenda (including extraordinary motions) has been fully discussed, the Chairperson shall not adjourn the meeting without resolution. If the Chairperson breaches procedure by prematurely adjourning the meeting, attending Directors shall assist shareholders in electing a new Chairperson by majority vote to continue the meeting.

The Chairperson shall ensure adequate explanation and discussion of all proposals and amendments. When discussion is deemed sufficient, the Chairperson may announce the end of discussion and proceed to vote, ensuring adequate time for voting is provided.

Article 11 (Shareholder Remarks)

Before speaking at the shareholders' meeting, attending shareholders shall complete a speech slip indicating the subject of the speech, shareholder account number (or attendance card number), and name. The Chairperson shall determine the order of speeches.

Shareholders who submit a speech slip but do not speak shall be deemed to have not spoken. If the speech content differs from that stated on the slip, the actual speech shall prevail.

Each shareholder may speak on the same proposal no more than twice and for no longer than five minutes per instance, unless otherwise approved by the Chairperson. The Chairperson may stop any shareholder who violates the rules or speaks off-topic.

During a shareholder's speech, other shareholders shall not speak or interrupt unless permitted by both the Chairperson and the speaker. The Chairperson shall stop any disruptions.

If a corporate shareholder appoints more than one representative to attend, only one representative may speak on any single proposal.

After a shareholder speaks, the Chairperson may respond personally or designate a relevant

person to respond.

For virtual meetings, shareholders participating online may submit questions in text form via the virtual platform after the Chairperson announces the opening of the meeting and until the announcement of adjournment. Each proposal may be questioned no more than twice, with a limit of 200 characters per question. These shareholders are not subject to the restrictions in the first to fifth paragraphs.

Article 12 (Calculation of Voting Rights and Recusal Requirements)

Voting at shareholders' meetings shall be calculated based on the number of shares held.

In making resolutions at shareholders' meetings, the shares of shareholders without voting rights shall not be included in the total number of issued shares.

Shareholders who have a conflict of interest with the Company on any proposal that may harm the Company's interests shall not vote nor exercise voting rights on behalf of others.

The shares of shareholders restricted from voting as described above shall not be counted in the number of voting rights represented by attending shareholders.

Unless the shareholder is a trust company or a shareholder services agent approved by the competent authority, any person receiving proxies from two or more shareholders shall not vote on behalf of shares exceeding 3% of the total voting rights of issued shares. Any excess shall not be counted.

Article 13 (Voting, Vote Counting, and Scrutineering Procedures)

Each share held by a shareholder entitles the shareholder to one vote, except for restricted shares or shares without voting rights as provided in Article 179, Paragraph 2 of the Company Act.

The Company shall allow shareholders to vote electronically and may also allow voting in writing. The methods of voting shall be specified in the meeting notice. Shareholders voting in writing or electronically shall be deemed to have attended in person but shall be considered to have abstained from voting on ad hoc motions or amendments to original proposals.

Shareholders who vote electronically or in writing shall ensure that their intent is received by the Company at least two days before the meeting. In case of duplicates, the earliest submission shall prevail unless a later submission explicitly revokes the earlier one.

If a shareholder has already voted electronically or in writing and wishes to attend in person or virtually, they must revoke their previous vote using the same method at least two days before the meeting. Failure to revoke in time means the original vote shall prevail. If a shareholder has also issued a proxy, the proxy vote shall prevail.

Unless otherwise provided by the Company Act or the Articles of Incorporation, proposals shall be passed by a majority of the voting rights represented at the meeting.

When voting, the Chairperson or a designated person shall announce the total number of voting rights represented, after which shareholders shall vote. The results of voting—approvals, rejections, and abstentions—shall be reported on the Market Observation Post System (MOPS) on the same day.

If a proposal has amendments or alternatives, the Chairperson shall determine the voting sequence. Once one version passes, all others shall be deemed rejected without further voting.

Vote scrutineers and counters shall be appointed by the Chairperson, but scrutineers must be shareholders.

Vote counting for resolutions or elections shall take place publicly at the meeting venue. Results, including vote counts, shall be announced immediately after counting and recorded.

For virtual meetings, shareholders shall vote via the virtual platform after the Chairperson announces the opening of the meeting and before the Chairperson announces the end of voting. Late votes shall be deemed abstentions.

In virtual meetings, vote counting shall be done once after the Chairperson announces the end of voting, and the results of resolutions and elections shall be announced.

For hybrid meetings, shareholders who registered for virtual attendance under Article 6 and wish to attend in person must cancel their virtual registration at least two days before the meeting via the same method; otherwise, they may only attend virtually.

Shareholders who voted in writing or electronically and have not revoked such votes but also attend the meeting virtually may not vote again, propose amendments, or vote on any amendments, except for ad hoc motions.

Article 14 (Election Matters)

When the shareholders' meeting includes the election of directors, it shall be conducted in accordance with the Company's relevant election rules, and the results, including the names of elected directors and their vote counts, shall be announced immediately.

Ballots from such elections shall be sealed and signed by scrutineers, properly preserved, and retained for at least one year. If a shareholder files a lawsuit under Article 189 of the Company Act, the ballots shall be retained until the conclusion of litigation.

Article 15 (Meeting Minutes and Signing Requirements)

Resolutions of shareholders' meetings shall be recorded in meeting minutes, signed or sealed by the Chairperson, and distributed to shareholders within 20 days after the meeting. The minutes may be produced and distributed electronically.

The Company may distribute the minutes by posting them on the Market Observation Post System (MOPS).

The meeting minutes shall include the year, month, and day of the meeting, the location, the Chairperson's name, the method of resolution, the essentials of the proceedings, and the voting results (including vote counts). In elections, the vote counts for each candidate shall be disclosed. The minutes shall be permanently retained during the Company's existence.

For virtual meetings, in addition to the above, the minutes shall include the start and end times, meeting format, names of the Chairperson and minute taker, and any contingency handling in case of disruptions to the virtual meeting platform or participation due to force majeure.

If the Company convenes a virtual-only meeting, the minutes shall also record the alternative

measures provided for shareholders who experience difficulties with virtual participation.

Article 16 (Public Announcements)

On the day of the meeting, the Company shall prepare a summary table showing the number of shares solicited by solicitors, represented by proxies, and represented by shareholders voting in writing or electronically, and display it clearly at the venue. For virtual meetings, this data shall be uploaded to the virtual meeting platform at least 30 minutes before the meeting and remain accessible until the meeting ends.

For virtual meetings, the total number of shares represented shall be disclosed on the platform at the time the meeting is called to order. If updated during the meeting, such updates shall also be disclosed.

If the resolutions passed involve material information under relevant laws or TPEx regulations, the Company shall disclose such information on MOPS within the prescribed timeframe.

Article 17 (Maintenance of Order at the Venue)

Meeting personnel shall wear identification badges or armbands.

The Chairperson may instruct marshals or security personnel to help maintain order. Marshals or security personnel assisting at the venue shall wear armbands or badges labeled "Marshal."

If the venue is equipped with a sound system, shareholders may only use Company-provided equipment to speak. The Chairperson may stop those who violate this rule.

If a shareholder violates the rules of procedure, disobeys the Chairperson’s instructions, and disrupts the meeting, the Chairperson may instruct marshals or security personnel to remove the individual.

Article 18 (Recess and Continuation of the Meeting)

During the meeting, the Chairperson may announce a recess at an appropriate time. If force majeure occurs, the Chairperson may temporarily suspend the meeting and announce a time to resume.

If the meeting venue becomes unavailable before the agenda (including extraordinary motions) is completed, the meeting may be relocated by resolution of the shareholders.

The shareholders’ meeting may also be postponed or continued within five days by resolution pursuant to Article 182 of the Company Act.

Article 19

For virtual shareholders’ meetings, the Company shall disclose the results of all voting and elections on the virtual platform immediately after the end of voting.

Article 20

When convening a virtual shareholders’ meeting, the Chairperson and the minute taker shall be at the same physical location within the territory of the Republic of China. The Chairperson shall

announce the address of that location at the start of the meeting.

Article 21

For virtual shareholders' meetings, the Chairperson shall announce at the beginning of the meeting that, except in cases where continuation or postponement is not required as specified under Paragraph 4, Article 44-20 of the Regulations Governing the Administration of Shareholder Services of Public Companies, if force majeure causes disruptions to the virtual meeting platform or participation for more than 30 minutes before the meeting is adjourned, the meeting shall be postponed or continued within five days. This shall not be subject to Article 182 of the Company Act.

Shareholders who did not register for virtual participation in the original meeting shall not attend the postponed or continued meeting.

For shareholders who registered for virtual participation and completed check-in but do not attend the continued or postponed meeting, their attendance, voting rights, and election rights from the original meeting shall be included in the counts for the postponed or continued meeting.

When a meeting is postponed or continued in accordance with the first paragraph, items for which voting and counting have been completed and results announced, including director elections, do not need to be discussed or resolved again.

In the case of a hybrid meeting, if the virtual platform becomes nonfunctional as described in the first paragraph but a legal quorum is still present excluding the virtual participants, the meeting shall continue. The shares represented by virtual participants shall be counted in the quorum, but their votes shall be deemed abstentions on all proposals.

Article 22

When the Company convenes a virtual shareholders' meeting, it shall provide appropriate alternative measures for shareholders who experience difficulty participating virtually.

Article 23

These Rules shall take effect upon approval by the shareholders' meeting. Amendments shall be subject to the same procedure.

These Rules of Procedure were established on December 8, 2010. The first amendment was made on April 12, 2013. The second amendment was made on June 27, 2014. The third amendment was made on May 22, 2020. The fourth amendment was made on May 18, 2023.

Appendix 2

AmCad BioMed Corporation
Articles of Incorporation

Chapter I－General Provisions

Article 1 The Company is organized in accordance with the Company Act and is named "安克生醫股份有限公司" in Chinese and "AmCad BioMed Corporation" in English.

Article 2 The Company shall engage in the following business activities:

1、 CE01010 General Instrument Manufacturing

2、 CE01030 Optical Instrument Manufacturing

3、 CE01990 Other Optical and Precision Instruments Manufacturing

4、 CZ99990 Other Unclassified Industrial Product Manufacturing

5、 E605010 Computer Equipment Installation Services

6、 F108031 Wholesale of Medical Devices

7、 F113030 Wholesale of Precision Instruments

8、 F208031 Retail Sale of Medical Devices

9、 F213040 Retail Sale of Precision Instruments

10、F213990 Retail Sale of Other Machinery and Equipment

11、F218010 Retail Sale of Information Software

12、F401010 International Trade

13、F601010 Intellectual Property Rights Services

14、I103060 Management Consulting Services

15、I199990 Other Consulting Services

16、I301010 Information Software Services

17、I301020 Data Processing Services

18、I301030 Electronic Information Supply Services

19、IG01010 Biotechnology Services

20、IG02010 Research and Development Services

21、IZ99990 Other Business Services

22、J399010 Software Publishing

23、CF01011 Medical Device Manufacturing

24、ZZ99999 All business activities not prohibited or restricted by laws and regulations, except those requiring special approval.

Article 3 The Company's head office is located in Taipei City. Branch offices may be established

domestically or internationally upon a resolution of the Board of Directors and approval by the competent authority, if required.

Article 4 The method of public announcement by the Company shall be conducted in accordance with Article 28 of the Company Act.

Chapter II – Shares

Article 5 The total authorized capital of the Company shall be NT$1,000,000,000, divided into 100,000,000 shares, each with a par value of NT$10. Of these, 3,000,000 shares shall be reserved for the issuance of employee stock options. The Board of Directors is authorized to issue the shares in installments as necessary.

Article 5-1 The Company may, with the approval of shareholders representing more than half of the total issued shares and by a resolution passed by at least two-thirds of the voting rights of shareholders present, transfer repurchased shares to employees at a price lower than the average repurchase price, or issue employee stock options at a subscription price lower than the closing price on the issuance date.

Article 6 The Company may provide external guarantees and may invest as a shareholder with limited liability in other companies. The total amount of such investments may exceed 40% of the Company's paid-in capital.

Article 7 The Company may issue registered shares without printing physical share certificates; however, the shares shall be registered with a centralized securities depository. If physical share certificates are printed, they shall be issued only after being duly signed or stamped by the directors representing the Company, affixed with the Company seal, and certified in accordance with applicable laws.

Employees who subscribe to new shares in accordance with Article 267 of the Company Act shall not transfer such shares within two years without the Company's consent; any transfer in violation of this provision shall be null and void.

Article 8 All matters relating to shareholder services shall be handled in accordance with the Company Act and the "Regulations Governing the Administration of Shareholder Services of Public Companies" as promulgated by the competent authority.

Article 9 The Company shall suspend the transfer of shares for a period of 60 days before the annual shareholders' meeting, 30 days before an extraordinary shareholders' meeting, or 5 days prior to the record date for distribution of dividends, bonuses, or other benefits.

Chapter III – Shareholders' Meetings

Article 10 The shareholders' meetings of the Company are classified into two types：

1.Annual Shareholders' Meeting：convened once a year by the Board of Directors in accordance with the law within six months after the end of each fiscal year.

2.Extraordinary Shareholders' Meeting: convened by the Board of Directors as necessary in accordance with the law.

Shareholders' meetings may be held via video conferencing or other methods announced by the central competent authority.

Article 11 The Chairperson of the Board shall preside over the shareholders' meeting. If the Chairperson is on leave or otherwise unable to perform duties, the Vice Chairperson shall act as proxy. If both the Chairperson and Vice Chairperson are on leave or unable to perform duties, the Chairperson shall designate a Director to act as proxy. If no proxy is designated, the Directors shall elect one among themselves to act as Chairperson.

Article 12 Notice of an annual shareholders' meeting shall be given to all shareholders at least 30 days in advance; notice of an extraordinary shareholders' meeting shall be given at least 15 days in advance.

If the recipient consents, the notice may be given electronically.

Article 13 A shareholder who is unable to attend a shareholders' meeting may issue a proxy form printed by the Company, specifying the scope of authorization and appointing a proxy to attend the meeting. The method of proxy attendance shall be handled in accordance with Article 177 of the Company Act and the "Regulations Governing the Use of Proxies for Attendance at Shareholders' Meetings of Public Companies" issued by the competent authority.

Article 14 Unless otherwise provided or restricted by laws and regulations, each share of the Company shall carry one voting right.

Article 15 Except where otherwise provided by laws and regulations, a resolution of the shareholders' meeting shall be adopted by shareholders representing more than half of the total issued shares being present in person or by proxy, and approved by a majority of the voting rights represented at the meeting.

Article 16 Resolutions of the shareholders' meeting shall be recorded in minutes, signed or sealed by the Chairperson of the meeting, and distributed to shareholders within twenty days after the meeting.

The distribution of the minutes shall be conducted in accordance with Article 183 of the Company Act.

Chapter IV – Directors, Board of Directors, and Managers

Article 17 The Company shall have 9 to 13 Directors, including no fewer than 3 Independent Directors and at least one-fifth of the total number of Directors. The number of

Directors to be elected shall be resolved by the Board of Directors. Directors shall be elected using a candidate nomination system in accordance with Article 192-1 of the Company Act, and selected from the list of candidates at the shareholders' meeting. Each Director shall serve a term of three years and may be re-elected.

The nomination, election, and related matters for Directors shall be handled in accordance with the Company Act and relevant regulations of the competent securities authority.

The shareholding ratio of all Directors shall comply with the "Regulations Governing Minimum Number of Shares Held by Directors and Supervisors of Public Companies" as prescribed by the competent authority.

Article 18 In accordance with Article 14-4 of the Securities and Exchange Act, the Company shall establish an Audit Committee composed entirely of Independent Directors. The Audit Committee or its members shall exercise the powers of Supervisors as provided under the Company Act, the Securities and Exchange Act, and other applicable laws and regulations.

Article 18-1 In accordance with Article 14-6 of the Securities and Exchange Act, the Company shall establish a Remuneration Committee. The Committee or its members shall perform duties in accordance with the "Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of Companies Whose Stock is Listed on the Stock Exchange or Traded Over the Counter."

Article 19 If the number of Directors falls short by one-third or all Independent Directors are dismissed, the Board of Directors shall convene a shareholders' meeting within 60 days to hold a by-election. The newly elected Directors shall serve only for the remainder of the original term.

Article 20 The Board of Directors shall be composed of all Directors and shall have the following powers:

1.Preparing business plans.
2.Proposing distribution of earnings or coverage of losses.
3.Proposing capital increases or decreases.
4.Establishing important bylaws and organizational rules.
5.Appointing and dismissing the Company's managerial officers.
6.Establishing or abolishing branch offices.
7.Preparing budgets and final accounts.
8.Other powers granted under the Company Act or by resolutions of the shareholders' meeting.

Article 21 The Board of Directors shall elect a Chairperson and a Vice Chairperson from among themselves by a majority vote of at least two-thirds of the Directors present at a meeting attended by a majority of all Directors. The Chairperson shall represent the

Company externally and may, for business needs, designate a Director to act on behalf of the Chairperson in the office.

Article 22 Except as otherwise provided by the Company Act, meetings of the Board of Directors shall be convened by the Chairperson. Resolutions of the Board shall, unless otherwise required by the Company Act, be adopted by a majority of the Directors present at a meeting attended by a majority of the Directors.

Article 23 Notice of a Board meeting shall state the purpose of the meeting and be given to each Director at least seven days in advance. In urgent circumstances, meetings may be convened at any time.
Notice may be given in writing, by fax, or electronically.

Article 24 The Chairperson of the Board shall preside over Board meetings. If the Chairperson is on leave or otherwise unable to perform duties, the Vice Chairperson shall act as proxy. If both are unable to perform duties, the Chairperson shall designate a Director to act as proxy. The Chairperson may also designate a Director to act on their behalf at the office for business purposes. If no proxy is designated, the Directors shall elect one among themselves.
Directors shall attend Board meetings in person. If unable to attend, a Director may appoint another Director as proxy. However, a proxy may only act for one other Director per meeting.

Board meetings may be conducted via video conferencing. Directors participating by video shall be deemed present in person.

Article 25 The remuneration of all Directors shall be determined by the Board of Directors and may be paid at prevailing industry standards regardless of Company profit or loss. The Company may purchase liability insurance for Directors during their term of office to cover duties performed on behalf of the Company.

Article 26 The Company may appoint managerial officers. Their appointment, dismissal, and remuneration shall be handled in accordance with Article 29 of the Company Act. The Company may purchase liability insurance for managerial officers for duties performed within the scope of their responsibilities.

Chapter V – Accounting

Article 27 The Company's fiscal year shall begin on January 1 and end on December 31 of each year. The Company shall conduct year-end closing procedures accordingly.

Article 28 At the end of each fiscal year, the Board of Directors shall prepare：(1) the business report,(2) the financial statements, and (3) proposals for profit distribution or loss compensation,which shall be submitted to the annual shareholders' meeting for approval in accordance with the law.

Article 29 Dividends and bonuses shall be distributed to shareholders in proportion to the number of shares held. No dividends or bonuses shall be distributed when there is no profit.

Article 30 If the Company generates profit in a given fiscal year (profit is defined as pre-tax earnings before the deduction of employee compensation and director compensation), and after offsetting accumulated losses, if there remains a balance, no less than 3% and no more than 6% shall be allocated as employee compensation (of which no less than 20% shall be distributed to grassroots employees), and no more than 4% shall be allocated as director compensation. Such allocations shall be made pursuant to a resolution adopted by at least two-thirds of the directors present at a Board meeting attended by more than half of all directors.

The aforementioned employee compensation and grassroots employee compensation may be distributed in the form of cash or shares, and may include employees of affiliated companies who meet certain criteria.

Article 31 If the Company generates earnings upon final accounting for the year, after paying all taxes and making up for past losses, it shall appropriate 10% as legal reserve and make adjustments to the special reserve as required by law. The remaining surplus, along with undistributed earnings from previous years, shall be allocated—at least 10% of which shall be proposed by the Board of Directors as a profit distribution plan and submitted to the shareholders' meeting for approval.

The Company's dividend policy shall be determined by the Board of Directors based on operational plans, investment projects, capital budgets, and internal and external environmental changes, and shall be distributed upon approval by the shareholders' meeting.

The distribution of earnings shall be made in an appropriate proportion of cash dividends and stock dividends. If stock dividends are distributed, they shall account for at least 10% of the total dividends for the year. The actual allocation ratio may be adjusted based on the Company's cash flow, profitability, and the need for future business expansion.

Article 32 Shareholders entitled to receive dividends and bonuses must be those listed in the shareholders' register five days prior to the record date for such distributions.

Chapter VI – Supplementary Provisions

Article 33 The Company's organizational rules and administrative guidelines shall be established separately.

Article 34 Any matters not provided for in these Articles of Incorporation shall be handled in accordance with the provisions of the Company Act.

Article 35 These Articles of Incorporation were established and agreed upon by all promoters at

the promoters' meeting on November 21, 2008, and shall take effect upon approval and registration by the competent authority. The first amendment was made on September 23, 2009. The second amendment was made on December 8, 2010. The third amendment was made on May 6, 2011. The fourth amendment was made on October 19, 2012. The fifth amendment was made on April 12, 2013. The sixth amendment was made on June 27, 2014. The seventh amendment was made on May 27, 2015. The eighth amendment was made on May 24, 2016. The ninth amendment was made on June 7, 2017. The tenth amendment was made on May 18, 2023. The eleventh amendment was made on June 3, 2025.

Appendix 3

AmCad BioMed Corporation
Rules for Director Elections

Article 1：To ensure fair, just, and transparent election of directors, this procedure is established in accordance with Article 21 of the "Corporate Governance Best-Practice Principles for TWSE/GTSM Listed Companies".

Article 2：The election of directors in our company shall be conducted in accordance with the provisions of this procedure, except as otherwise provided by laws or the company's articles of incorporation.

Article 3：The selection of directors in this company should take into account the overall composition of the board of directors. The composition of the board of directors should consider diversity, and appropriate diversity policies should be formulated based on its own operations, business type, and development needs. These policies should include but not be limited to the following two aspects:

1.Basic conditions and values: gender, age, nationality, culture, etc.

2.Professional knowledge and skills: professional background (such as law, accounting, industry, finance, marketing, or technology), professional skills, and industry experience, etc.

The members of the board of directors should generally possess the knowledge, skills, and qualities necessary for performing their duties. The overall abilities that they should possess are as follows:

1.Operational judgment ability.

2.Accounting and financial analysis ability.

3.Management ability.

4.Crisis handling ability.

5.Industry knowledge.

6.International market perspective.

7.Leadership ability.

8.Decision-making ability.

More than half of the seats on the board of directors should not be held by individuals who have a spouse or a relative within two degrees of kinship.

Article 4：The qualifications of the Company’s independent directors shall comply with Articles 2, 3, and 4 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies.

The election of the Company’s independent directors shall comply with Articles 5, 6, 7, 8, and 9 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies, and shall be conducted in accordance with Article 24 of the Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies.

Article 5：The election of directors in this company shall follow the procedures of candidate nomination system as prescribed in Article 192-1 of the Company Act. In case of dismissal of directors due to reasons, resulting in the number of directors being less than five, the company shall hold a by-election at the nearest shareholders' meeting. However, if the number of vacancies for directors reaches one-third of the seats stipulated in the articles of association, the company shall hold a special shareholders' meeting to fill the vacancies within 60 days from the occurrence of the fact.

If the number of independent directors is insufficient according to the provisions of Subparagraph 1, Paragraph 2 of Article 14-2 of the Securities and Exchange Act, the company shall make up for the vacancy at the nearest shareholders' meeting. If all independent directors are dismissed, the company shall hold a special shareholders' meeting within 60 days from the occurrence of the fact to elect new independent directors.

Article 6：The election of the directors of this company adopts the system of cumulative voting by a single ballot, and each share has the same number of voting rights as the number of directors to be elected. Shareholders can concentrate their votes on one candidate or distribute their votes among multiple candidates.

Article 7：The Board of Directors should prepare election ballots equal to the number of directors to be elected and indicate the voting rights on each ballot. The ballots should be distributed to the shareholders attending the shareholders' meeting, and the names of the voters may be recorded on the ballots by filling in their attendance registration number.

Article 8：The number of directors in this company is determined by the company's articles of association, and the election rights of independent directors and non-independent directors are counted separately. The candidate who receives the most votes representing the election rights for each category of director will be elected in order. In case there are two or more candidates with the same number of votes and exceeding the prescribed number of seats, they will be determined by drawing lots. If a candidate is absent, the chairman shall draw lots on their behalf.

Article 9：Before the start of the election, the chairman should designate several shareholders as inspectors and vote counters to perform their duties. The ballot box should be prepared by the board of directors and opened for inspection by the inspectors before the vote.

Article 10：Invalid ballots shall include any of the following circumstances:

1.Ballots not prepared by the convener.
2.Blank ballots submitted to the ballot box.
3.Illegible or altered handwriting.
4.The name of the candidate written on the ballot does not match the list of nominated directors.
5.Other words or phrases written on the ballot in addition to the assigned voting rights.
6.Two or more candidates selected on the same ballot.

Article 11：After the voting is completed, the ballots shall be counted on the spot, and the result of

the count shall be announced on the spot by the chairman or a person designated by the chairman, including the list of elected directors and their number of votes.

The ballots for the election shall be sealed and signed by the scrutineers and properly kept for at least one year. However, if shareholders file a lawsuit under Article 189 of the Company Law, they shall be kept until the end of the litigation.

Article 12：This regulation shall take effect after being passed by the shareholders' meeting, and the same shall apply when it is revised.

This regulation was established on December 8, 2010. The 1st amendment was made on June 27, 2014. The 2nd amendment was made on May 24, 2016. The 3rd amendment was made on May 21, 2021.

Appendix 4

AmCad BioMed Corporation
Shareholding Status of Directors

1. A breakdown of the number of shares held by directors：

April 14, 2026 (Book closure date)

Job title	Name	Number of shares registered in the register of shareholders	Remark
Chairman	Lee Yi-Li	582,327	
Vice Chairman	Phytohealth Corp.	22,155,049	Representative：Lee I-Lin
Director	Phytohealth Corp.	22,155,049	Representative：Lee Chen-Chia
Director	Chang King-Jen	2,902,000	
Director	Maywufa Company Ltd.	3,994,996	Representative：Sheu Jin-Chuan
Director	Phytohealth Corp.	22,155,049	Representative：Chen Wal-ter
Director	Jen Yu Ltd.	46,000	Representative：Chiou Shu-Ti
Director	Maywufa Company Ltd.	3,994,996	Representative：Wang Tsay-Ping
Director	Jen Yu Ltd.	46,000	Representative：Gary T. Tseng
Independent Director	Chang Ching-Tian	0	
Independent Director	Huang Weng-Foung	0	
Independent Director	Li Hsueh-Yu	0	
Independent Director	Lin She-Yi	0	

2. The minimum number of shares held by all directors and the detailed list of the number of shares held by the shareholder register：

April 14, 2026 (Book closure date)

Job title	Number of shares to be held	Number of shares registered in theregister of shareholders
Director	5,066,632	29,680,372

Remarks：

(1)The Company’s paid-in capital is NT$633,329,000, divided into 63,332,900 shares.

(2)The Company has appointed more than two Independent Directors. In accordance with Article 2 of the “Regulations Governing Minimum Number of Shares Held by Directors and Supervisors of Public Companies and the Verification Thereof,” the minimum shareholding requirement for all Directors is reduced to 80% of the originally prescribed ratio.

(3)Independent Directors are excluded from the calculation of Directors’ shareholdings.